66 kDa ANTIGEN FROM BORRELIA

Abstract: Nucleic acid fragments are disclosed which encode a polypeptide antigen reactive with antisera from rabbits immunised with a 66 kDa protein from Borrelia garinii IP90. The presence of nucleic acid fragments encoding such a polypeptide antigen as well as the presence of the polypeptide antigen have been demonstrated in three strains of B. Burgdorferi sensu lato, but are substantialle absent from at least 95 % of randomly selected B. hermsii, B. crocidurae, B. anserina, and B. hispanica. The encoded polypeptide is surface exposed on the bacterial surface, it is highly conserved, and is thus potentially useful as a vaccine agent and as a diagnostic agent in the diagnosis of infections with B. burgdorferi as are the characteristic nucleic acid fragments of the invention. Also disclosed are methods of producing the polypeptide antigen according to the invention as are antibodies directed against the antigen.

Description: 66 kDa ANΗGEN FROM BORRELIA Mention is made of U.S. Serial Nos.079,601 filed 23 June 1993, 137,175 filed 26 October 1993, 262,220filed 20 June 1994, 320,416 filed 3 October 1994, and 375,993 filed 20 January 1995, each incorporated herein by reference; and, this application is a continuation-in-part of U.S. Serial No.262,220. The present invention relates to nucleic acid fragments encoding antigenic proteins associated with Borrelia burg- dorferi sensu lato (Borrelia burgdorferi sensu stricto, Borrelia garinii , and Borrelia afzelii ; denoted Bb herein) , particularly polypeptides associated with virulence of the bacteria. The invention also relates to methods for producing Bb immunogenic polypeptides and corresponding antibodies. Other embodiments of the invention relate to compositions and methods for detecting Lyme disease and also vaccines against infections with Borrelia burgdorferi sensu lato are a part of the invention as is methods of immunizing animals against diseases caused by these infections. Vectors and transformed cells comprising Bb-associated nucleic acids are also included. DESCRIPTION OF RELATED ART Lyme disease is a multisystem disease resulting from tick transmission of the infectious agent, Bb (Rahn and Malawista, 1991) . Although recognized as a clinical entity within the last few decades (Steere et al., 1977), case reports resem¬ bling Lyme disease date back to the early part of the 20th century. Cases of the disease have been reported in Europe, Asia and North America (Schmid, 1985) . Despite a relatively low total incidence compared to other infectious diseases, Lyme disease represents a significant health problem because of its potentially severe cardiovascular, neurologic and arthritic complications, difficulty in diagnosis and treat¬ ment and high prevalence in some geographic regions. Bb is not a homogeneous group but has a variable genetic content, which may in turn affect its virulence, pattern of pathogenesis and immunogenicity. Lyme borreliosis associated borreliae are so far taxonomically placed into three species, Borrelia burgdorferi sensu stricto, Borrelia garinii , and Borrelia afzelii (Burgdorfer et al. 1983, Baranton et al. 1992, Canica et al. 1993). It is well documented that con¬ siderable genetic, antigenic and immunogenic heterogeneity occurs among them, as well as among the strains within the separate species (Baranton et al. 1992, Canica et al. 1993, Zingg et al. 1993, ilske et al. 1993, Adam et al. 1991, Marconi and Garon 1992) . The major evidence of this pheno¬ menon is provided by the molecular studies of the plasmid-en- coded outer surface protein A (OspA) , B (OspB) , and C (OspC) (Barbour et al. 1984, Jonsson et al. 1992, Wilske et al. 1993, Marconi et al. 1993). In different animal models effi¬ cient protection is achieved by passive and active immuniza¬ tion with OspA (Simon et al., 1991 Fikrig et al., 1992, Erdile et al., 1993), therefore, OspA remains one of the main candidates for a Borrelia vaccine. It is unclear, however, whether inter- and intra-species heterogeneity of OspA, as well as other competitors for i munoprophylaxis, allow effi¬ cient cross-protection (Fikrig et al. 1992, Norris et al., 1992) . Furthermore, it was recently suggested that certain protective antibodies produced early in the course of Borrelia infection are unrelated to OspA (Norton Hughes et al., 1993, Barthold and Bockenstedt, 1993). Its virulence factors, pathogenetic mechanisms and means of immune evasion are unknown. At the level of patient care, diagnosis of the disease is complicated by its varied clini¬ cal presentation and the lack of practical, standardized diagnostic tests of high sensitivity and specificity. Antimicrobial therapy is not always effective, particularly in the later stages of the disease. Variation among Bb strains and species and the changes resul¬ ting from in vitro passage add to the problems of developing vaccines or immunodiagnostics from either the whole organism or specifically associated proteins. Using a PCR assay, it was found that one set of oligonucleotide primers was speci¬ fic for North American Bb isolates, another for most European isolates and a third set recognized all Bb strains (Rosa et al., 1989) . Serological assays for the diagnosis and detection of Lyme disease are thought to offer the most promise for sensitive and specific diagnosis. However, serologic assays generally use whole Bb as the antigen and suffer from a low "signal to noise" ratio, i.e., a low degree of reactivity in positive samples, particularly early in the disease, as compared to negative samples. This problem results in high numbers of false negatives and the potential for false positives. Back¬ ground reactivity in negative controls may be due in part to conserved antigens such as the 41K flagellin and the 60K "Common Antigen". These Bb proteins possess a high degree of sequence homology with similar proteins found in other bacteria. Therefore- normal individuals will often express anti-flagellar and anti-60K antibodies. Unique, highly reac¬ tive Bb antigens for serological assays are therefore desir¬ able but heretofore unavailable. Diagnosis of Lyme disease remains a complex and uncertain endeavour, due to lack of any single diagnostic tool that is both sensitive and specific. Clinical manifestations and history are the most common bases for diagnosis. However, there is a pressing need for specific, sensitive, reprodu¬ cible and readily available confirmatory tests. Direct detec- tion offers proof of infection but is hampered by the ex¬ tremely low levels of Bb that are typically present during infection, as well as the inaccessibility of sites that tend to be consistently positive (e.g., heart and bladder). Cul¬ ture, although sensitive, is cumbersome and requires 1-3 weeks to obtain a positive result. PCR appears to offer promise in terms of direct detection (Lebech et al., 1991) and indeed Goodman et al (1991) have reported detection of Bb DNA in the urine of patients with active Lyme disease using a PCR method. However, it is unlikely that PCR assays will become commonly used in clinical laboratories because of the degree of skill required for its use and the high risk of DNA contamination. Another problem in detection of Lyme disease is the substan¬ tial number of humans exposed to Bb who develop unapparent or asymptomatic infections. This number has been estimated as high as 50% (Steere et al., 1986). There is clearly a need for means of preparing Bb-specific antigens, e.g., for the development of diagnostic tests for Lyme disease or vaccines against Lyme disease. Adequate assays do not exist and should ideally meet several criteria, including (1) expression of an antigen by all pathogenic Bb strains, (2) elicitation of an immune response in all Lyme disease patients, (3) high immunogenicity with a detectable antibody response early in the infection stage, (4) antigens unique to Bb without cross reactivity to other antigens and, (5) distinction between individuals exposed to nonpathogenic as opposed to pathogenic forms of Bb. Problems similar to those relating to diagnosis exist when attempting to prepare a vaccine against diseases caused by Bb. Successful single antigen vaccines have until now not been prepared, possibly due to the inter-strain and inter- species antigenic variation. As mentioned above, OspA has been the main candidate for the immunogenic constituent of a single antigen vaccine, but time has proven that in order for such a vaccine to be efficient it has to contain OspA from at least three different Bb species (Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii) . A number of investigators have reported the presence of proteins with molecular weights in the region between 60 and 75 kDa. Many of these proteins are also recognised by anti¬ bodies in patient sera when analyzed by Western blots. (Bar¬ bour 1984, Luft et al., 1989). Protease treatment of Borrelia burgdorferi cells (Barbour et al. 1984) showed that a minor protein with an apparent molecular weight of 66 kDa was accessible to proteolytic cleavage, and hence probably asso¬ ciated with the outer envelope. Coleman and Benach (1987) isolated a protein with apparent molecular weight of 66 kDa from an outer envelope fraction isolated from Borrelia burg- dorferi B31. However, direct amino acid sequencing of Bb proteins with the apparent molecular weights 66-, 68-, 71-, and 73-kDa revealed these proteins to have high sequence similarity with the E. coli heat-shock proteins (Luft et al., 1991) making them less suitable for the use in prophylaxis and serodiagnosis. SUMMARY OF THE INVENTION The inventors have surprisingly found that an antigen from Bb with an apparent molecular weight of 66 kDa (determined by SDS-PAGE, and staining with Coomassie Blue) is highly con- served in the three strains B. burgdorferi sensu stricto B31, B. garinii IP90, and B. afzelii ACAI, whereas this antigen cannot be found in Borrelia species related to relapsing fever and avian borreliosis. The disclosed antigens therefore are excellent candidates for vaccines and diagnostics rela- ting to infections with Bb. Thus, the present invention addresses one or more of the foregoing or other problems associated with the preparation and use of Bb specific antigens, particularly those antigens which are associated with virulence and which are useful for developing detection and diagnostic methods for Lyme disease as well as vaccines against Lyme disease. The invention involves the identification of such antigens, as well as the identification and isolation of Bb nucleic acid sequences that encode Bb antigens or antigenic polypeptides derived therefrom. These sequences are useful for preparing expres¬ sion vectors for transforming host cells to produce recombi¬ nant antigenic polypeptides. It is further proposed that these antigens will be useful as vaccines or as immunodiag- nostic agents for Bb associated diseases such as Lyme disease in particular. The DNA disclosed herein was isolated from the bacterium Borrelia burgdorferi sensu lato hereafter designated as Bb. The microorganism is a spiral-shaped organism approximately 0.2 micron in diameter and ranging in length from about 10-30 microns. Like other spirochetes, it possesses an inner mem¬ brane, a thin peptidoglycan layer, an outer membrane, and periplasmic flagella which lie between the inner and outer membranes. Bb is obligate parasite found only in association with infected animals and arthropod vectors in endemic areas. Bb-like organisms have also been identified in birds raising the possibility that birds could also serve as an animal reservoir. While some Bb isolates have been cloned, most isolates have not been cloned and most likely represent mixtures of different variants even at the time of culture origination. Bb has similarities with other relapsing fever organisms such as B. hermsii . Bb has a single chromosome with two unusual features, linear conformation and small size (approximately 900 kilobase pairs) . Fresh isolates of Bb contain up to four linear plasmids and six circular supercoiled plasmids. The plasmid content of different Bb isolates is highly variable. For example, in one study only two of thirteen strains had similar plasmid profiles. Some plasmids are lost during in vi tro passage which may correlate with loss of virulence. Outer surface proteins OspA and OspB are encoded on the 49 kbp linear plasmid. The 66 kDa membrane-associated proteins discovered by the inventors are encoded on the Bb chromosome. In order to identify DNA segments encoding the 66 kDa pro¬ teins, purified protein was isolated from B. afzelii ACAI, by preparative SDS-PAGE for subsequent use in amino acid sequen¬ cing. The peptide was transferred to polyvinylene diffusable membranes, sequence analysis was performed using standard sequencing techniques (Ma sudaira, 1987) . An 8 amino acid sequence was identified (SEQ ID NO: 1). Codons for the amino acid sequence were selected by reverse translation based on (1) conclusion that codons containing A or T were favoured and (2) knowledge of published DNA sequences for several Bb proteins. A choice favouring A or T containing codons was based on the observation that the G + C content of Bb DNA is only 28-35% (Burman et al. 1990). A 24 nucleotide segment was synthesized having the structure in SEQ ID NO: 2 (correspon¬ ding to amino acids 6-13) : 5' - GAA AAA GAT ATW TTT AAA ATW AAT - 3' (SEQ ID NO: 2) -wherein W denotes the bases A or T, i.e. the 24 nucleotide segment exists in 4 variants. DNA libraries were prepared by restriction enzyme digestion of DNA prepared from B. burgdorferi B31, B. afzelii ACAI and B . garinii Ip90. The 24 residue oligonucleotide probe was used as a probe to screen the DNA library prepared from B. garinii Ip90 to identify DNA encoding the 66 kDa protein isolated from this Bb species. A 592 bp DNA fragment coding for part of the 66 kDa protein from B. garinii Ip90 was used as a probe to screen DNA libraries prepared from B. burgdorferi B31 and B. afzelii ACAI to identify DNA encoding the 66 kDa protein from these Bb species. Antigenicity of the 66 kDa protein was determined. Antiserum collected from rabbits injected with the 66 kDa protein prepared from B. garinii Ip90 was shown to react with the 66 kDa proteins, as detected on immunoblots of B. garinii Ip90 as well as B. burgdorferi B31 and B. afzelii ACAI. No reac¬ tive spots were detected in normal rabbit serum. This result should lead to straightforward production of monoclonal antibodies reactive with the 66 kDa polypeptides from one strain of one species exclusively as well as from two or all three species. Antibodies could be produced and used for screening strains for protein expression, for determining structural location and for examining bactericidal activity of antibodies against these proteins. The nucleic acid segments of the present invention thus encode amino acid sequences associated with Bb. Some of these amino acid sequences are antigenic. The nucleic acid sequences are also important for their ability to selectively hybridize with complementary stretches of Bb gene segments. Varying conditions of hybridization may be desired, depending on the application envisioned and the selectivity of the probe toward the target sequence. Where a high degree of selectivity is desired, one may employ relatively stringent conditions to form the hybrids, such as relatively low salt and/or high temperature conditions. Under these conditions, little mismatch between the probe and template or target strand is tolerated. Less stringent conditions might be employed where, for example, one desires to prepare mutants or to detect mutants when significant divergence exists. In clinical diagnostic embodiments, nucleic acid segments of the present invention may be used in combination with an appropriate means, such as a label, to determine hybridiza¬ tion with DNA of a pathogenic organism. Typical methods of detection might utilize, for example, radioactive species, enzyme-active or other marker ligands such as avidin/biotin, which are detectable directly or indirectly. In preferred diagnostic embodiments, one will likely desire to employ an enzyme tag such as alkaline phosphatase or peroxidase rather than radioactive or other reagents that may have undesirable environmental effects. Enzyme tags, for example, often uti¬ lize colorimetric indicator substrates that are readily detectable spectrophotometrically, many in the visible wave¬ length range. Luminescent substrates could also be used for increased sensitivity. Hybridizable DNA segments may include any of a number of segments of the disclosed DNA. For example, relatively short segments including 12 or so base pairs may be employed, or, more preferably when probes are desired, longer segments including 20, 30 or 40 base pairs, depending on the particu¬ lar applications desired. Shorter segments are preferred as primers in such applications as PCR, while some of the longer segments are generally preferable for blot hybridizations. It should be pointed out, however, that while sequences dis¬ closed for the DNA segments of the present invention are defined by SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7, and SEQ ID NO: 13, a certain amount of variation or base substi¬ tution would be expected, e.g., as may be found in mutants or strain variants, but which do not significantly affect hybri¬ dization characteristics. Such variations, including base modifications occurring naturally or otherwise, are intended to be included within the scope of the present invention. While the 66 kDa Bb antigen has been disclosed in terms of specific amino acid sequences from three strains of Bb, it is nonetheless contemplated that the amino acid sequence will be found to vary even further from species to species and iso- late to isolate. Moreover, it is quite clear that changes may be made in the underlying amino acid sequence through e.g., site-directed mutagenesis of the DNA coding sequence, in a way that will not negate its antigenic capability. The invention also relates to at least partially purified antigenic Bb proteins or polypeptides capable of eliciting an in vivo immunogenic response in animals which are later challenged with Bb. These proteins may comprise all or part of the amino acid sequence encoded by the herein disclosed DNA. Particularly preferred antigenic proteins have the amino acid sequence shown in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 14. These proteins, as well as their epito- pes, will be useful in connection with vaccine development, and as antige (s) in i munoassays for detection of Bb anti¬ bodies in biological fluids such as serum, seminal or vaginal fluids, urine, saliva, body exudates and the like. In other aspects, the invention concerns recombinant vectors such as plasmids, phage or viruses, which comprise DNA seg¬ ments in accordance with the invention, for use in replica¬ ting such sequences or even for the expression of encoded antigenic peptides or proteins. Vectors or plasmids may be used to transform a selected host cell. In preparing a suit¬ able vector for transforming a cell, desired DNA segments from any of several Bb sources may be used, including genomic fragments, cDNA or synthetic DNA. In practice of the present invention, an expression vector may incorporate at least part of the DNA sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 13 encoding one or more epitopic segments of the disclosed 66 kDa antigens. Expression vectors may be constructed to include any of the DNA segments disclosed herein. Such DNA might encode an antigenic protein specific for virulent strains of Bb or even hybridization probes for detecting Bb nucleic acids in samples. Longer or shorter DNA segments could be used, depen¬ ding on the antigenic protein desired. Epitopic regions of the 66 kDa proteins expressed or encoded by the disclosed DNA could be included as relatively short segments of DNA. A wide variety of expression vectors is possible including, for example, DNA segments encoding reporter gene products useful for identification of heterologous gene products and/or resistance genes such as antibiotic resistance genes which may be useful in identifying transformed cells. Recombinant vectors such as those described are particularly preferred for transforming bacterial host cells. Accordingly, a method is disclosed for preparing transformed bacterial host cells that includes generally the steps of selecting a suitable bacterial host cell, preparing a vector containing a desired DNA segment and transforming the selected bacterial host cell. Several types of bacterial host cells may be employed, including Bb, E. coli , B. subtilis, and the like as well as other suitable pro- and eukaryotic host cells. Transformed cells may be selected using various techniques, including screening by differential hybridization, identifi : cation of fused reporter gene products, resistance markers, anti-antigen antibodies and the like. After identification of an appropriate clone, it may be selected and cultivated under conditions appropriate to the circumstances, as for example, conditions favouring expression or, when DNA is desired, replication conditions. Another aspect of the invention involves the preparation of antibodies and vaccines from the antigenic 66 kDa proteins or epitopic regions of that protein encoded by the disclosed DNA. The invention thus relates to one or more antibodies, monoclonal or polyclonal, that may be generated in response to the 66 kDa Bb proteins or their epitopes. It is expected that the sensitivity and specificity of antibody response to this 66 kDa proteins and their epitopes will be superior to the response that has been obtained from other Bb antigens that are not associated with virulence. Previous work with several Bb antigens isolated from both virulent and avirulent strains indicated low sensitivity when immunofluorescence and ELISA assays were employed, especially during early stages of infection. In both immunodiagnostics and vaccine preparation, it is often possible and indeed more practical to prepare antigens from segments of a known immunogenic protein or polypeptide. Certain epitopic regions may be used to produce responses similar to those produced by the entire antigenic polypeptide. Potential antigenic or immunogenic regions may be identified by any of a number of approaches, e.g., Jame- son-Wolf or Kyte-Doolittle antigenicity analyses or Hopp and Woods (1981) hydrophobicity analysis (see, e.g., Jameson and Wolf, 1988; Kyte and Doolittle, 1982; or U.S. Patent No. 4,554,101). Hydrophobicity analysis assigns average hydrophi- licity values to each amino acid residue from these values average hydrophilicities can be calculated and regions of greatest hydrophilicity determined. Using one or more of these methods, regions of predicted antigenicity may be derived from the amino acid sequence assigned to the 66 kDa polypeptide. Regions from the 66 kDa antigens having a high likelihood of being epitopes include the sequences correspon- ding to positions 175-190, 285-305, 365-385, and 465-490. It is contemplated that the antigens and immunogens of the invention will be useful in providing the basis for one or more assays to detect antibodies against Bb. Previous assays have used whole Bb as the antigen. Sera from normal indivi- duals not exposed to Bb often contain antibodies that react with Bb antigens, in particular antigens that have epitopes in common with other bacteria. It is necessary to adjust assay conditions or the diagnostic threshold of reactivity to avoid false positive reactions due to these cross-reactive antibodies in normal sera. These adjustments may in turn decrease the sensitivity of the assay and lead to false negative reactions, particularly in the early stages of Bb infection. Assays using the disclosed 66 kDa proteins or antigenic polypeptides thereof, are expected to give superior results both in sensitivity and selectivity when compared to assays that use whole Bb or even purified flagella in either an indirect ELISA or an antibody capture ELISA format. Wes¬ tern im unoblots based on reactions with such antigens (whole Bb, flagella and the like) have been difficult to interpret due to the presence of antibodies in sera from unexposed individuals. These antibodies cross-react with Bb antigens, most particularly the 41 kDa flage11in and the 60 kDa common antigen protein. Generally, assays which use whole organisms or purified flagella tend to contain antigens with epitopes that will cross react with other bacterial antigens. For example, the N and C terminal regions of the Bb flagellin possess 52-55% sequence identity with the Salmonella typhimu- rium and Bacillus subtilis sequences (Wallich et al., 1990), exemplifying the highly conserved nature of flagellin struc- ture. The 60 kDa Bb protein is likewise 58 homologous with the E. coli protein (Shanafelt et al., 1991). Such cross reactivity is not likely with the 66 kDa antigen, which is apparently unique to Bb. It is further anticipated that a recombinant derived 66 kDa Bb protein will be particularly preferred for detecting Bb infections. Unexposed individuals should have a low reacti¬ vity to one or more epitopes of the 66 kDa proteins thereby making it possible to use lower dilutions of serum and increase sensitivity. Using a combination of more than one of these unique antigens may also enhance sensitivity without sacrificing specificity. Preferred immunoassays are contemplated as including various types of enzyme linked immunoassays (ELISAS) , immunoblot techniques, and the like, known in the art. However, it readily appreciated that utility is not limited to such assays, and useful embodiments include RIAs and other nonen- zyme linked antibody binding assays or procedures. Yet another aspect of the invention is a method of detecting Bb nucleic acid in a sample. The presence of Bb nucleic acid in the sample may be indicated by the presence of the polypeptide products which it encodes. The method therefore includes detecting the presence of at least a portion of any of the polypeptides herein disclosed. Suitable detection methods include, for example, immunodetection reagents, PCR amplification, and hybridization. Yet another aspect of the invention includes one or more primers capable of priming amplification of the disclosed DNA of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 13. Such primers are readily generated taking into account the base sequence of the DNA segment of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 13, the disclosed DNA, or deriving a base sequence from the amino acid sequence of a purified polypeptide encoded by the DNA. Primers are analo¬ gous to hybridization probes, but are generally relatively short DNA segments, usually about 7-20 nucleotides. Methods of diagnosing Lyme disease are also included in the invention. In one embodiment, an antibody-based method includes obtaining a sample from a patient suspected of having Lyme disease, exposing that sample to one or more epitopes of the Bb protein which is encoded by the DNA dis¬ closed and finally determining a reactivity of the antibody with one or more epitopes of a Bb protein that may be in the sample. The reactivity measured is indicative of the presence of Lyme disease. Typical samples obtainable from a patient include human serum, plasma, whole blood, cerebrospinal fluid, seminal or vaginal fluids, exudates and the like. Several variations of antibody-based methods are contemplated for development; for example, an indirect ELISA using the 66 kDa proteins or other Bb proteins as an antigen. The 66 kDa proteins may be produced in large quantities by recombinant DNA vectors already disclosed and purified. Optimal concen¬ tration of the antigen could be determined by checker board titration and diagnostic potential of the 66 kDa proteins assay examined further by testing serum from mice at diffe- rent stages of infection and infected with different strains of Bb. These results could indicate the relative time course for sera conversion for each of the assays and would also show whether infection with different strains causes vari¬ ation in anti-66 kDa protein titers. Likewise, reactive epitopes of the 66 kDa polypeptides are contemplated as useful either as antigens in an ELISA assay or to inhibit the reaction of antibodies toward intact 60 kDa proteins bound to a well. Epitopic peptides could be gene¬ rated by recombinant DNA techniques previously disclosed or by synthesis of peptides from individual amino acids. In either case, reaction with a given peptide would indicate presence of antibodies directed against more epitopes. In addition to its diagnostic potential, this method is seen as being particularly effective in characterizing monoclonal antibodies against the 66 kDa proteins and other virulence associated proteins. In further aspects, the present invention concerns a kit for the detection of Bb antigens, the kit including, alternative¬ ly, an antibody reactive with 66 kDa antigenic proteins or a protein or peptide which includes an epitope thereof, together with means for detecting a specific immunoreaction between an antibody and its corresponding antigen. Examples of suitable means include labels attached directly to the antigen or antibody, a secondary antibody having specificity for human Ig, or protein A or protein G. Alternatively, avidin-biotin mediated Staphylococcus aureus binding could be used. For example, the monoclonal antibody may be biotinyla- ted so as to react with avidin complexed with an enzyme or fluorescent compound. A particular embodiment of the invention concerns kits for detection of antibodies against the described Bb 66 kDa antigens, epitopes thereof as represented by portions of the amino acid sequences, or closely related proteins or pep¬ tides, such as epitopes associated with other virulence- associated proteins detected by comparison of low-passage, virulent and high-passage, avirulent strains of Bb. The antigen for the kit(s) consists of the Bb 66 kDa proteins or portions thereof produced by a recombinant DNA vector in E. coli or another bacterial or nonbacterial host. Alternative¬ ly, the antigen may be purified directly from Bb or manufac- tured as a synthetic peptide. Samples for the assays may be body fluids or other tissue samples from humans or animals. The presence of " reactive antibodies in the samples may be demonstrated by antibody binding to antigen followed by detection of the antibody-antigen complex by any of a number of methods, including ELISA, RIA, fluorescence, agglutination or precipitation reactions, nephelometry, or any of these assays using avidin-biotin reactions. The degree of reacti¬ vity may be assessed by comparison to control samples, and the degree of reactivity used as a measure of present or past infection with Bb. The assay(s) could also be used to monitor reactivity during the course of Lyme disease, e.g., to deter¬ mine the efficacy of therapy. In still further embodiments, the invention contemplates a kit for the detection of Bb nucleic acids in the sample, wherein the kit includes one or more nucleic acid probes specific for the 66 kDa genes, together with means for detec- ting a specific hybridization between such a probe and Bb nucleic acid, such as an associated label. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hence, the invention relates to an isolated nucleic acid fragment comprising a nucleotide sequence which - encodes a polypeptide exhibiting a substantial immunolo¬ gical reactivity with a rabbit antiserum raised against a 66 kDa polypeptide derived from Borrelia garinii IP90, said rabbit ant-iserum exhibiting substantially no immuno¬ logical reactivity with whole cell preparations (prepared as described herein) from at least 95% of randomly selected Borrelia hermsii, Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica. It is preferred that the 66 kDa polypeptide used for rising the rabbit antiserum and derived from Borrelia garinii IP90 comprises the amino acid sequence 1-600 in SEQ ID NO: 8. By the term "nucleic acid fragment" as used herein is meant a fragment of DNA or RNA, but also of PNA (cf. Nielsen P E et al . , 1991), having a length of at least two joined nucleoti¬ des. It will be understood, that although the disclosed nucleic acid fragments of the present invention are DNA fragments, it may be desirable to employ a RNA fragment in e.g. a viral vector, the genome of which is natively composed of RNA. For the purposes of preparing e.g. probes for hybri¬ dization assays as described below, PNA fragments may prove useful, as these artificial nucleic acids have been demon¬ strated to exhibit very dynamic hybridization properties. The term "a substantial immunological reactivity" is meant to designate a marked immunological binding between an anti- body/antiserum on the one hand, and on the other an antigen, under well-defined conditions with respect to physicochemical parameters as well as concentrations of antigens and anti¬ bodies. Thus, a substantial immunological reactivity should be clearly distinguishable from a non-specific interaction between an antibody/antiserum and an antigen. This distinc¬ tion can for instance be made by reacting the anti- body/antiserum with a known concentration of an antigen which has previously been shown not to react with the anti- body/antiserum, and then using this reaction as a negative control. A positive control could suitably be the reaction between the antibody/antiserum and the same concentration of the antigen used for the immunisation resulting in the pro¬ duction of the antibody/antiserum. In such an assay, an antigen resulting in a relative signal of at least 10% (cal¬ culated as S m - (S p -S n ) -100, where S m is the measured signal, S p the positive control signal, and S n the negative control signal) is regarded as having a substantial immunological reactivity. An antigen exhibiting "substantially no immunolo¬ gical reactivity" therefore is defined as an antigen giving a signal of less than 10%. Although the data presented herein demonstrates that there is no cross-reactivity between antigens from Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica and the disclosed polypeptides, it is conceivable that a few isolates of these bacteria will exhibit some cross-reacti¬ vity. As can be deduced from the above it is expected that the cross-reactivity will be less than 5% (since there is no reactivity with at least 95% of randomly chosen Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica) , and according to the invention this cross-reac¬ tivity may be even lower, such as at the most 4% and 3%, preferably at the most 2%, such as 1%. According to the invention the cross-reactivity is most preferred at most %, such as 0%. In such a case there will be no substantial immunological reactivity between the rabbit antiserum men¬ tioned above and whole cell preparations of Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispani ¬ ca. The above-cited considerations concerning cross-reactivity apply for all cross-reactions between on the one hand the polypeptides/DNA fragments of the invention and on the other hand material from Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. When using the term "cross-reactivity" is herein meant the phenomenon that two species exhibit a common feature which is detected in a reaction. In the present context the term cross-reactivity is used for similar reactions in antigen- antibody interactions as well as in hybridization interac- tions. Nucleic acid fragments of the invention useful as hybridisation probes and/or primers are not necessarily those fragments encoding immunologically useful polypeptides. Therefore the invention also relates to nucleic acid frag- men s which hybridises readily with either a DNA fragment having the nucleotide sequence SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with a DNA fragment complemen¬ tary thereto, but exhibits no substantial hybridization with genomic DNA from at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica when the hybridization conditions are highly stringent. Preferred nucleic acid fragments of the invention are DNA fragments, especially those which have nucleotide sequences with a sequence homology of at least 70% with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with subse¬ quences thereof. However, the degree of homology may be even higher such as at least 75%, 80%, 85%, 87%, and 89%. It is preferred that the degree of homology is at least 90%, such as 92%, 94% or 95%, and especially preferred are DNA frag¬ ments with a sequence homology of at least 96% with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13. Espe¬ cially for high accuracy hybridization assays, a total homology is necessary, and therefore preferred. Other pre¬ ferred nucleotide acid fragments of the invention are those which encode a polypeptide of the invention (cf. the below discussions concerning these polypeptides and their degree of homology with the amino acid sequences disclosed herein) which has an amino acid sequence exhibiting a sequence homology of at least 50% with SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ NO: 10, or SEQ ID NO: 14 or with subsequences thereof. The terms "homology" and "homologous" are, with respect to DNA fragments, intended to mean a homology between the nu¬ cleotides in question between which the homology is to be established, in the match with respect to identity and posi- tion of the nucleotides of the DNA fragments. With respect to polypeptides and fragments thereof described herein, the terms are intended to mean a homology between the amino acids in question between which the homology is to be established, in the match with respect to identity and position of the amino acids of the polypeptides. Considerations similar to those given above for the immuno¬ logical reactivity and cross-reactivity of antigens can be applied for the distinction between a nucleic acid fragment which "hybridizes readily" and a fragment which "exhibits substantially no hybridization" under high stringency condi¬ tions. The term "highly stringent" when used in conjunction with hybridisation conditions is as defined in the art, i . e. 5- 10°C under the melting point T m , cf. Sambrook et al, 1989, pages 11.45-11.49. Interesting nucleic acid fragments of the invention encode a polypeptide comprising an amino acid sequence comprised in a polypeptide present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, and/or Borrelia afzelii ACAI but substantially absent from whole cell pre¬ parations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica. This encoded polypeptide may according to the invention comprise at least a part of an amino acid sequence of a 66 kDa protein which is present in Bb, and it is pre¬ ferred that the polypeptide encoded by the nucleic acid fragment of the invention is a 66 kDa protein present in whole cell preparations, and preferably this 66 kDa protein is also present in fraction B (as discussed in the examples) . It is especially preferred that the encoded polypeptide further is a natively surface exposed protein of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. By the terms "present" and "substantially absent", when referring to amino acid sequences and polypeptides in bacteria, are meant that the concentration of the amino acid sequence/polypeptide in a bacterium where it is "present" is at least 100 times higher than in a bacterium where it is substantially absent. However, it is preferred that the ratio of the concentrations are at least 1000, and more preferred at least 10,000, 100,000 or even higher. It is especially preferred that there can be observed no concentration of the amino acid sequence/polypeptide in the bacterium from where it is substantially absent. It will be understood from the above that various analogues and subsequences of the nucleic acids disclosed herein are interesting aspects of the invention, as are nucleic acid fragments encoding fused polypeptides including polypeptides encoded by nucleic acid fragments of the invention. The term "analogue" with regard to the nucleic acid fragments of the invention is intended to indicate a nucleotide sequence which encodes a polypeptide identical or substan¬ tially identical to a polypeptide encoded by a nucleic acid fragment of the invention (SEQ ID NO's: 4, 6, 8 and 14). It is well known that the same amino acid may be encoded by various codons, the codon usage being related, inter alia, to the preference of the organisms in question expressing the nucleotide sequence. Thus, one or more nucleotides or codons of a nucleic acid fragment of the invention may be exchanged by others which, when expressed, result in a polypeptide identical or substantially identical to the polypeptide encoded by the nucleic acid fragment in question. Also, the term "analogue" is used in the present context to indicate a nucleic acid fragment or a nucleic acid sequence of a similar nucleotide composition or sequence as the nucleic acid sequence encoding the amino acid sequence having the immunological properties discussed above, allowing for minor variations which do not have an adverse effect on the biological function and/or immunogenicity as compared to the disclosed polypeptides, or which give interesting and useful novel binding properties or biological functions and immuno- genicities etc. of the analogue. The analogous nucleic acid fragment or nucleic acid sequence may be derived from an animal or a human or may be partially or completely of syn¬ thetic origin as described herein. The analogue may also be derived through the use of recombinant nucleic acid tech¬ niques. Furthermore, the terms "analogue" and "subsequence" are intended to allow for variations in the sequence such as substitution, insertion (including introns) , addition, dele¬ tion and rearrangement of one or more nucleotides, which variations do not have any substantial effect on the poly¬ peptide encoded by a nucleic acid fragment or a subsequence thereof. The term "substitution" is intended to mean the replacement of one or more nucleotides in the full nucleotide sequence with one or more different nucleotides, "addition" is understood to mean the addition of one or more nucleotides at either end of the full nucleotide sequence, "insertion" is intended to mean the introduction of one or more nucleotides within the full nucleotide sequence, "deletion" is intended to indicate that one or more nucleotides have been deleted from the full nucleotide sequence whether at either end of the sequence or at any suitable point within it, and "re- arrangement" is intended to mean that two or more nucleotide residues have been exchanged with each other. A preferred method of preparing variants of the 66 kDa antigens disclosed herein is site-directed mutagenesis. This technique is useful in the preparation of individual pep- tides, or biologically functional equivalent proteins or peptides, derived from the 66 kDa antigen sequences, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being tra¬ versed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the technique of site-specific mutagenesis is well known in the art as exemplified by publications (Adelman et al., 1983). As will be appreciated, the technique typical¬ ly employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing et al., 1981). These phage are readily commer¬ cially available and their use is generally well known to those skilled in the art. In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector which includes within its sequence a DNA sequence which encodes the 66 kDa antigens. An oligonucleotide primer bear¬ ing the desired mutated sequence is prepared, generally synthetically, for example by the method of Crea et al. (1978) . This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heterodu- plex is formed wherein one strand encodes the original non- mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as E. coli cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement. The preparation of sequence variants of the selected 66 kDa genes using site-directed mutagenesis is provided as a means of producing potentially useful species of the 66 kDa genes and is not meant to be limiting as there are other ways in which sequence variants of the 66 kDa genes may be obtained. For example, recombinant vectors encoding the desired 66 kDa genes may be treated with mutagenic agents to obtain sequence variants (see, e.g., a method described by Eichenlaub, 1979) for the mutagenesis of plasmid DNA using hydroxylamine. Another example is the possibility of introducing point mutations in the disclosed sequences by use of PCR tech¬ niques, wherein the primers used include mismatches which, after the completion of the PCR cycles, appear in the ampli¬ fication products. The thus obtained amplified mutated nucleic acid fragments can thereafter be introduced into suitable vectors and used for the production of recombinantly transformed host cells. Analogues/subsequences of the disclosed nucleic acid frag¬ ments which also form part of the invention are nucleic acid fragments which are fused to at least one other nucleic acid fragment which encodes a protein enhancing the immunogenicity of the fused protein relative to a protein without the encoded fusion partner. Such encoded proteins may e.g. be lipoproteins, e.g. the outer membrane lipoprotein from E. coli and OspA from Borrelia burgdorferi sensu lato; viral proteins, e.g. from Hepatitis B surface antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1; immunoglobulin binding proteins, e.g. protein A, protein G, and the synthetic ZZ-peptide; T-cell epitopes; or B-cell epitopes. Other nucleic acid fragments to form part of a nucleic acid fragment of the invention encoding a fusion polypeptide are those encoding polypeptides which facilitates expression and/or purification of the fused peptide. Such encoded polypeptides could according to the invention be bacterial fimbrial proteins, e.g. the pilus components pilin and papA; protein A; the ZZ-peptide; the maltose binding protein; gluthatione S-transferase; /3-galactosidase; or poly- histidine. Other nucleic acid fragments of the invention of special interest are those encoding at least one epitope present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of ran¬ domly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. Preferred are epitopes of a ββ kDa protein present in whole cell prepara¬ tions of Bb. By the term "epitope" is meant the spatial part of an antigen responsible for the specific binding to the antigen-binding part of an antibody. It goes without saying that the identi- fication of epitopes of the disclosed antigens will facili- tate the production of polypeptides which exhibit marked antigenicity thus making them interesting with respect to diagnosis of Borreliosis and vaccination against infections with Bb. The identification of epitopes can be performed in several ways. One possibility is to make a hydrophobicity plot as described herein, and thereafter selecting the special linear sequences of the polypeptide and investigate their immunogen- icity. As mentioned herein, several regions of the disclosed polypeptides are regarded as interesting. Thus, nucleic acids encoding polypeptides substantially identical to the amino acid sequences 175-190, 285-305, 365-385, or 465-490 in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 also form part of the invention; such nucleic acid fragments may also be part of nucleic acid fragments encoding fusion polypeptides comprising multiple copies of at least one of epitope, as such fusion polypeptides should exhibit superior immunological utility in diagnostics as well as in vaccines. Another way of simply identifying epitopes is to digest a polypeptide antigen with a known amino acid sequence with endo- and exopeptidases. The obtained fragments are tested against antibodies directed against the whole polypeptide, and by way of deduction, the precise location of the linear epitopes can be determined. A variation of this method involves the recombinant production of subfragments (cf. the above) of the full-length polypeptide followed by the same test procedure. Another part of the invention relates to a substantially pure polypeptide exhibiting a substantial immunological reactivity with an antiserum from rabbits immunised with a 66 kDa polypeptide derived from Borrelia garinii IP90, said rabbit antiserum exhibiting substantially no immunological reacti¬ vity with whole cell preparations from at least 95% of ran¬ domly selected B. hermsii , B. crocidurae, B. anserina, or B. hispanica. It is preferred that the 66 kDa polypeptide used for rising the rabbit antiserum and derived from Borrelia garinii IP90 comprises the amino acid sequence 1-600 in SEQ ID NO: 8. It will be understood that such a polypeptide may be encoded by a DNA fragment of the invention and that the polypeptides encoded by the DNA fragments of the invention also form part of the invention. By the term "polypeptide" is herein understood a molecule comprising at least two amino acids joined by a peptide bond. The term polypeptide thus indicate small peptides (less than 10 amino acid residues) , oligopeptides (between 10 and 100 amino acid residues) , proteins (the functional entity inclu¬ ding at least one peptide and/or prosthetic groups and/or glycosylation and/or lipidation etc.) as well as traditional polypeptides (more than 100 amino acid residues) . Interesting polypeptides according to the invention are those prepared by the well known methods of liquid or solid phase peptide synthesis utilizing the successive coupling of the individual amino acids of the polypeptide sequence. Alterna- tively, the polypeptide can be synthesized by the coupling of individual amino acids forming fragments of the polypeptide sequence which are later coupled so as to result in the de¬ sired polypeptide. These methods thus also constitute another interesting part of the invention. Preferred polypeptides of the invention are recombinant polypeptides, normally prepared by a process comprising inserting a nucleic acid fragment of the invention in an expression vector, transforming a host organism or a host cell (normally a host organism or host cell which does not natively express the polypeptide of the invention) with the vector, culturing the transformed host cell under conditions facilitating the expression of the polypeptide by the host organism or host cell, harvesting the polypeptide, and optionally subjecting the polypeptide to post-translational modification(s) , and performing an at least partial purification of the polypeptide. The need for post-translational modifications exists because certain polypeptides are prepared in the above-described manner lacking for instance a fatty-acylation of an amino acid residue, or the polypeptide have for some reason been prepared in an elongated version which should be cleaved before the polypeptide will prove functional. Thus, according to the invention the post-translational modifications involves lipidation, glycosylation, cleavage, or elongation of the polypeptide. In some instances, the host cell or cell line also processes the translation product so as to obtain a processed polypeptide. The present invention thus also relates to the use of the nucleic acid fragments of the invention in the construction of vectors and in host cells. The following is a general discussion relating to such use and the particular conside¬ rations in practising this aspect of the invention. In general, of course, prokaryotes are preferred for the initial cloning of nucleic sequences of the invention and constructing the vectors useful in the invention. For example, in addition to the particular strains mentioned in the more specific disclosure below, one may mention by way of example, strains such as E. coli K12 strain 294 (ATCC No. 31446), E. coli B, and E. coli X 1776 (ATCC No. 31537). These examples are, of course, intended to be illustrative rather than limiting. Prokaryotes are also preferred for expression. The aforementioned strains, as well as E. coli W3110 (F-, lamb¬ da-, prototrophic, ATCC No. 273325), bacilli such as Bacillus subtilis, or other enterobacteriaceae such as Salmonella t phiimiriuin or Serratia marcesans , and various Pseudomonas species may be used. In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322, a plasmid derived from an E. coli species (see, e.g., Bolivar et al. , 1977). The pBR322 plasmid contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which can be used by the microorganism for expression. Those promoters most commonly used in recombinant DNA con¬ struction include the B-lactamase (penicillinase) and lactose promoter systems (Chang et al., 1978; Itakura et al., 1977; Goeddel et al., 1979) and a tryptophan (trp) promoter system (Goeddel et al., 1979; EPO Appl. Publ. No. 0036776). While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebwenlist et al., 1980). Certain genes from proka- ryotes may be expressed efficiently in E. coli from their own promoter sequences, precluding the need for addition of another promoter by artificial means. In addition to prokaryotes, eukaryotic microbes, such as yeast cultures may also be used. Saccharomyces cerevisiase, or common baker's yeast is the most commonly used among eukaryotic microorganisms, although a number of other strains are commonly available. For expression in Saccharomyces, the plasmid YRp7, for example, is commonly used (Stinchcomb et al., 1979; Kingsman et al., 1979; Tschemper et al., 1980). This plasmid already contains the trpl gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan for example ATCC No. 44076 or PEP4-1 (Jones, 1977) . The presence of the trpl lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzman et al., 1980) or other glycolytic enzymes (Hess et al., 1968; Holland et al., 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phospho- fructokinase, glucose-6-phosphate isomerase, 3-phosphoglyce¬ rate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expres¬ sion vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination. Other promoters, which have the additional advantage of transcription controlled by growth conditions are the promo¬ ter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Any plasmid vector containing a yeast- compatible promoter, origin of replication and termination sequences is suitable. In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In prin- ciple, any such cell culture is workable, whether from verte- brate or invertebrate culture. However, interest has been greatest in vertebrate cells, and propagation of vertebrate in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, 1973) . Examples of such useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7 293 and MDCK cell lines. Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences. For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40) . The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of repli- cation (Fiers et al., 1978). Smaller or larger SV40 fragments may also be used, provided there is included the approximate¬ ly 250 bp sequence extending from the Hindlll site toward the Bgll site located in the viral origin of replication. Fur¬ ther, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems. An origin of replication may be provided either by construc¬ tion of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) or may be provided by the host cell chromosomal replication mechanism. If the vector is inte¬ grated into the host cell chromosome, the latter is often sufficient. In the light of the above discussion, the methods for recom- binantly producing the polypeptide of the invention are also a part of the invention, as are the vectors carrying and/or being capable of replicating the nucleic acids according to the invention in a host cell or a cell-line. According to the invention the expression vector can be e.g. a plasmid, a cosmid, a minichromosome, or a phage. Especially interesting are vectors which are integrated in the host cell/cell line genome after introduction in the host. Another part of the invention are transformed cells (useful in the above-described methods) carrying and capable of replicating the nucleic acid fragments of the invention; the host cell can be a microorganism such as a bacterium, a yeast, or a protozoan, or a cell derived from a multicellular organism such as a fungus, an insect cell, a plant cell, or a mammalian cell. Especially interesting are cells from the bacterial species Escherichia, Bacillus and Salmonella, and a preferred bacterium is E. coli . Yet another part of the invention relates to a stable cell line producing a polypeptide according to the invention, and preferably the cell line carries and expresses a nucleic acid of the invention. Returning to the polypeptides of the invention: Also polypeptides which comprises an amino acid sequence exhibit- ing a sequence homology of at least 50% with SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ NO: 10, or SEQ ID NO: 14 or with subsequences thereof are interesting embodiments of the polypeptides of the invention. However this homology should normally be higher, such as at least 60%, 70%, 80%, 85%, or even 90%. Preferred polypeptides have a homology of at least 92%, such as at least 95%, 97%, 98%, 99%, or even 100%. Other preferred polypeptides of the invention are those which are encoded by a nucleic acid fragment of the invention (cf. the discussions above concerning these nucleic acid fragments and their degree of homology with the nucleic acid sequences disclosed herein) which has a nucleic acid sequence exhibi¬ ting a sequence homology of at least 70% with SEQ ID, NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with subse¬ quences thereof. A very important part of the invention is vaccines for con¬ ferring increased resistance to infection with Bb. Thus, an important part of the invention relates to vaccines comprising an amount of a polypeptide according to the inven¬ tion, the amount of the polypeptide being effective to confer substantially increased resistance to infections with Borrelia burgdorferi sensu lato in an animal, including a human being, optionally in combination with a pharmaceuti¬ cally acceptable carrier or vehicle and the vaccine optional¬ ly further comprising an adjuvant. Of course, also vaccines comprising polypeptide fragments encoded by the nucleic acid fragments of the invention are a part of the invention, as such polypeptide fragments as mentioned above also form part of the invention. By the term "conferring substantially increased resistance to infections" is meant that the administration of the vaccine to the animal has the effect that disease caused by infec¬ tions with at least one strain of bacteria is avoided or at least that the risk of catching the disease is significantly reduced. Part of the present invention contemplates vaccine prepara¬ tion and use. General concepts related to methods of prepara¬ tion and use are discussed in the following as applicable to preparations and formulations with the polypeptides of the invention. Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorpor- ated herein by reference. Typically, such vaccines are pre¬ pared as injectables either as liquid solutions or suspen¬ sions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharma¬ ceutically acceptable and compatible with the active ingredi¬ ent. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines. The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscu¬ larly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkalene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharma¬ ceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredi¬ ent, preferably 25-70%. The proteins may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeuti- cally effective and immunogenic. The quantity to be adminis¬ tered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner. However, suit¬ able dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 1 μg to 500 μg, especially in the range from about 10 μg to 50 μg. Suitable regimes for initial admini¬ stration and booster shots are also variable but are typified by an initial administration followed by subsequent inocula¬ tions or other administrations. The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologi¬ cally acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the size of the host. Various methods of achieving adjuvant effect for the vaccine include use of agents such as aluminum hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solution in phosphate buffered saline, admixture with synthetic polymers of sugars (Carbopol) used as 0.25 percent solution, aggrega¬ tion of the protein in the vaccine by heat treatment with temperatures ranging between 70° to 101°C for 30 second to 2 minute periods respectively. Aggregation by reactivating wit pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopoly- saccharide components of gramnegative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono- oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. In many instances, it will be desirable to have multiple administrations of the vaccine, usually not exceeding six vaccinations, more usually not exceeding four vaccinations and preferably one or more, usually at least about three vaccinations. The vaccinations will normally be at from two to twelve week intervals, more usually from three to five week intervals. Periodic boosters at intervals of 1-5 years, usually three years, will be desirable to maintain levels of the antibodies. The course of the immunization may be fol¬ lowed by assays for antibodies for the supernatant antigens. The assays may be performed by labelling with conventional labels, such as radionuclides, enzymes, fluorescers, and the like. These techniques are well known and may be found in a wide variety of patents, such as U.S. Patent Nos. 3,791,932; 4,174,384 and 3,949,064, as illustrative of these types of assays. It is contemplated that the vaccines of the invention should be effective in activating both arms of the immune system. Thus, vaccines capable of eliciting a cell-mediated immune reaction are also a part of the invention. One such vaccine of the invention is a live vaccine compri¬ sing a non-pathogenic microorganism carrying and being capable of expressing a nucleic acid fragment of the inven¬ tion, the live vaccine being effective in conferring increased resistance to infection with Borrelia burgdorferi sensu lato in an animal, including a human being. The non- pathogenic microorganism could for instance be a bacterium such as a strain of Mycobacterium bovis BCG. The live vaccine could for instance express a multitude of the polypeptides of the invention, thereby making it more immunogenic. Another way of eliciting a cell-mediated response is to employ an adjuvant as described above. However, recent research have revealed a new an exciting possibility, wherein a DNA fragment is introduced into non-replicating cells of the vaccinated animal, whereafter the translational product is exposed on the cell-surface thereby eliciting a cell- mediated response. These methods are reviewed in Ulmer et al., 1993, which hereby is included by reference. Therefore, also a part of the invention is a vaccine compri¬ sing a nucleic acid fragment according to the invention, the vaccine effecting in vivo expression of antigens by an ani¬ mal, including a human being, to whom the vaccine has been administered, the amount of expressed antigens being effec¬ tive to confer substantially increased resistance to infec¬ tions with Borrelia burgdorferi sensu lato in an animal, including a human being. It is also possible that a vaccine according to the invention comprising other Borrelia antigens may prove useful, as a more efficient immunological response could be elicited. Such a combination vaccine could for instance contain OspA, OspB, OspC, OspD, and/or PC. In this regard, also combination vaccines comprising at least two different polypeptides according to the invention are interesting. Methods of actively immunizing animals, including mammals such as human beings against infections with Bb are also parts of the invention. The methods generally consist of the administration to the animal of an immunogenically effective amount of the vaccines of the invention. Methods for passive immunisation comprising administering to the animal an immunogenically effective amount of an antibody of the inven¬ tion (as described below) are also included in the invention. An important part of the invention relates to at least par¬ tially purified antibodies, polyclonal or monoclonal, reac¬ ting substantially specifically with a protein according to the invention, or proteins encoded by the nucleic acid frag- ments of the invention. According to the invention, monoclonal antibodies are preferred. The phrase "reacting substantially specifically" is intended to indicate that the antibody will show no substantial immu¬ nological reactivity (as defined above) with other antigens which might possibly be present in an embodiment of the present invention where the antibody is used. The antibodies of the invention are prepared by methods well- known to the skilled person. Other important parts of the present invention are composi- tions adapted for the determination of Bb in animals (inclu¬ ding mammals, e.g. humans) . Accordingly, methods of determi¬ ning the presence of Bb are also a part of the invention. A diagnostic composition adapted for the determination of Borrelia burgdorferi sensu lato in an animal, including a human being, or in a sample, the composition comprising an amount of the polypeptide of the invention effective to detectably react with antibodies present in the animal or in the sample, the antibodies being directed against Borrelia burgdorferi sensu lato, the composition optionally comprising a detectable label, is also a part of the invention. Similar compositions including the nucleic acid fragments of the invention or the antibodies of the invention are also a part of the invention, as will be apparent from the claims. The phrase "to detactably react with" is intended to mean a reaction between two substances in an assay, the reaction being significant enough so as to give a signal in the assay which is clearly different from a negative signal. Thus, the detectable reaction is highly dependent on the type of detec- tion means used. Very sensitive methods like ELISAs and RIAs will detect reactions involving few molecules, whereas more insensitive reactions will demand that the reaction involves many molecules. Methods of determining the presence of Bb antibodies or components of Bb in samples or in animals are also parts of the invention, as is a method of determining the presence of antibodies directed against Borrelia burgdorferi sensu lato in an animal, including a human being, or in a sample, com- prising administering the polypeptide of the invention to the animal or incubating the sample with the polypeptide of the invention, and detecting the presence of bound antibody resulting from the administration or incubation. Likewise, a method of determining the presence of a Borrelia burgdorferi sensu lato antigen in an animal, including a human being, or in a sample, comprising administering an antibody of the invention to the animal or incubating the sample with the antibody, and detecting the presence of bound antigen resul¬ ting from the administration or incubation, forms part of the invention. Finally a method of determining the presence of Borrelia burgdorferi sensu lato nucleic acids in an animal, including a human being, or in a sample, comprising adminis¬ tering a nucleic acid fragment of the invention to the animal or incubating the sample with the nucleic acid fragment of the invention or a nucleic acid fragment complementary there¬ to, and detecting the presence of hybridized nucleic acids resulting from the incubation, is also included in the inven¬ tion. Finally, diagnostic kits for the diagnosis of on-going or previous Bb infection forms part of the invention. The diag¬ nostic kits of the invention comprises an antibody, a nucleic acid, or a polypeptide according to the invention in combina¬ tion with a means for detecting the interaction with the relevant substance reacting with these substances of the invention; the choice of these detection means is discussed elsewhere herein. In both the diagnostic methods, compositions, and kits the antibodies, nucleic acids or polypeptides according to the invention may optionally be coupled to solid or semi-solid carriers, as is well-known in the art. As will appear from the examples, the present invention relates to the utility of Bb associated antigenic proteins as diagnostic or preventive tools in Lyme disease. Proteins have been identified as associated only with virulent isolates of Bb, providing a basis for several types of diagnostic tests for infections with Bb and for Lyme disease, including im- munodiagnostic and nucleic acid identification, such as those based on amplification procedures (PCR etc.). It is contemplated that several assays for the presence of Bb or for Lyme disease may be developed using any of the polypeptides of the invention, the corresponding nucleic acid fragments encoding the protein, functionally similar proteins and their epitopes, or by detection of other appropriate nucleic acids. These methods are similar in principle to those previously described (Magnarelli et al., 1989; Magna- relli et al., 1984; and Craft et al. , 1984). Reactive epito¬ pes representing portions of the 66 kDa protein sequences could be utilized in an analogous manner. Another promising assay is the microcapsule agglutination technique (MCAT) (Arimitsu et al., 1991). In this procedure, microscopic polystyrene beads are coated with Bb antigen and incubated with dilutions of patient serum. After overnight incubation at 4°C, the agglutination patterns are determined. Using whole Bb as antigen, the MCAT has been shown to be highly discriminatory between Lyme disease patients and healthy individuals, with little overlap in agglutination titer, although false positive reactions have been observed with rheumatoid arthritis patients (Anderson et al., 1988) and leptospirosis samples (Barbour, 1988) . An assay using 66 kDa protein alone or in combination with other antigens such as the 94 kDA, 30 kDa and 21 kDa antigens should be feasible. Such combinations may increase sensitivity of the assay. Also contemplated within the scope of the present invention is the use of the disclosed nucleic acid fragments as hybri- dization probes. While particular examples are provided to illustrate such use, the following provides general back¬ ground for hybridization applications taking advantage of the disclosed nucleic acid sequences of the invention. The invention has disclosed a DNA segment encoding an antigenic Bb protein. Detection of that DNA or various parts thereof is expected to provide the basis for a useful assay. One method of detecting the 66 kDa antigen genes is based on selective amplification of known portions of the gene. A particular method utilizes PCR amplification, using any of a number of primers that could be prepared from knowledge of the nucleic acid sequence of SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7, and SEQ ID NO: 13. Generally, such primers are relatively short, e.g., 7-28 base pairs in length, and may be derived from the respective sense or anti-sense strands of the disclosed DNA segment. Synthesis of these primers may utilize standard phosphoramidite chemistry (Beaucage et al., 1981) . As mentioned, in certain aspects, the DNA sequence informa¬ tion provided by the invention allows for the preparation of relatively short DNA (or RNA or PNA) sequences having the ability to specifically hybridize to Bb gene sequences. In these aspects, nucleic acid probes of an appropriate length are prepared based on a consideration of the sequence, e.g., SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 13 or derived from flanking regions of these genes. The ability of such nucleic acid probes to specifically hybridize to the Bb gene sequences lend them particular utility in a variety of embodiments. Most importantly, the probes can be used in a variety of diagnostic assays for detecting the presence of pathogenic organisms in a given sample. However, either uses are envisioned, including the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructs. To provide certain of the advantages in accordance with the invention, the preferred nucleic acid sequence employed for hybridization studies or assays includes sequences that are complementary to at least a 10 to 40, or so, nucleotide stretch of the selected sequence, such as that shown in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 13. A size of at least 10 nucleotides in length helps to ensure that the fragment will be of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 10 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. Thus, one will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 20 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesi¬ zing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR tech¬ nology of U.S. Patent 4,603,102, or by introducing selected sequences into recombinant vectors for recombinant produc- tion. The present invention will find particular utility as the basis for diagnostic hybridization assays for detecting Bb- specific RNA or DNA in clinical samples. Exemplary clinical samples that can be used in the diagnosis of infections are thus any samples which could possibly include nucleic acid, including samples from tissue, blood serum, urine or the like. A variety of tissue hybridization techniques and sys¬ tems are known which can be used in connection with the hybridization aspects of the invention, including diagnostic assays such as those described in Falkow et al., U.S. Patent 4,358,535 which is hereby incorporated by reference. Accordingly, the nucleotide sequences of the invention are important for their ability to selectively form duplex mol¬ ecules with complementary stretches of Bb gene segments. Depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degree of selectivity of the probe toward the target sequence. For applications requiring a high degree of selec¬ tivity, one will typically desire to employ relatively strin¬ gent conditions to form the hybrids, for example, one will select relatively low salt and/or high temperature condi¬ tions, such as provided by 0.02M-0.15M NaCI at temperatures of 50°C to 70°C. These conditions are particularly selective, and tolerate little, if any, mismatch between the probe and the template or target strand. Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent hybri¬ dization conditions are called for in order to allow forma¬ tion of the heteroduplex. In these circumstances, one would desire to employ conditions such as 0.15 M-0.9 M salt, at temperatures ranging from 20°C to 55°C. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization condi¬ tions can be readily manipulated, and thus will generally be a method of choice depending on the desired results. In clinical diagnostic embodiments, nucleic acid sequences of the present invention are used in combination with an appro- priate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detect¬ able signal. In preferred diagnostic embodiments, one will likely desire to employ an enzyme tag such as alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known which employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with pathogen nucleic acid-containing samples. Luminescent substrates, which give off light upon enzymatic degradation, could also be employed and may provide increased sensitivity. In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) from suspected clinical samples, such as exudates, body fluids (e.g., amniotic fluid cerebrospinal fluid) or even tissues, is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The selected conditions will depend on the particular circumstances based on the particu¬ lar criteria required (depending, for example, on the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. Plasmids pJB-101, pJB-102, and pJB-104 have been deposited on the 16 June 1994 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the numbers DSM 9253, DSM 9254, and DSM 9255, respectively, under the terms and conditions of the Budapest Treaty. LEGENDS TO THE FIGURES Figs. IA and IB. Effect of proteases on B. afzelii ACAI cells. A: Coomassie blue-stained PAGE of the bacterial lysates after the cells were incubated with buffer alone, lane 1; trypsin, lane 2; or proteinase K, lane 3. B: PAGE of the subcellular fraction of membrane components (Fraction B) recovered from the cells treated in three dif¬ ferent ways described in section A. Arrows indicate the position of 66 kDa protein. Mw: molecular weight, kD: kiloda- lton. Figs. 2A and 2B. Comparison of phenotypic expression of the 66 kDa protein in Borrelia species. A: Coomassie blue-stained PAGE of the whole cell proteins of B. burgdorferi B31, lane 1; B. afzelii ACAI, lane 2; B gari ¬ nii Ip90, lane 3; B. hermsii , lane 4; B. crocidurae, lane 5; and B. anserina, lane 6. B: Reactivity of Borrelia proteins against rabbit anti-66 kDa protein antibody in Western blot. Borrelia species are num- bered as in section A. Arrow indicates the position of the 66 kDa protein. Mw: molecular weight, kD: kilodalton. Figs. 3A and 3B. Southern blot analysis of DNA. A: DNA separated by pulse-field agarose gel electrophoresis. Lane 1, DNA prepared from B. burgdorferi B31. Lane 2, DNA prepared from Borrelia afzelii ACAI. Lane 3, DNA prepared from Borrelia garinii Ip90. B: DNA subsequently transferred to a Hybond-N membrane and cross-linked with UV-light and probed at 55°C with a radiola- belled DNA probe derived by PCR amplification of the 66 kDa gene from Borrelia garinii Ip90. Lane 1, Lane 2 and Lane 3 same as above. Figs. 4A and 4B. Western blot analysis of recombinant 66 kDa protein expressed in E. coli . A: Proteins prepared from uninduced E. coli . B: Proteins prepared from induced E. coli . Proteins were separated by 12.5% SDS-PAGE and subsequently transferred to an Immobilon-P membrane by electroblotting. Non-specific binding was blocked by immersing the filter in 5% BSA. The proteins were visualised by using the rabbit anti-66 kDa serum as primary antibody and an alkaline phosphatase conjugated anti-rabbit IgG secondary antibody with a subsequent developing reaction using the substrate BCIP. Lane 1, proteins prepared from whole cells. Lane 2, proteins from the supernatant obtained after sonication. Lane 3, proteins obtained by extraction of the pellet after soni¬ cation with 2M urea. Lane 4, proteins obtained by further extraction of the pellet after sonication with 8M urea. Lane 5, fraction B prepared from B. garinii Ip90. Figs. 5A, 5B, and 5C. Plot of antigenicity index of the 66 kDa protein. The plots were made using the Jameson-Wolf algorithm provided in the MacVector software package. A: 66 kDa protein from B. burgdorferi B31. B: 66 kDa protein from B. afzelii ACAI. C: 66 kDa protein from B. garinii Ip90. EXAMPLES Bacterial strains and culture conditions. Borrelia strains used in this study were the following: strain B31 of B. burgdorferi , a tick isolate from North America (ATCC 35210) ; strain ACAI of B. afzelii , a human skin isolate from Sweden (Asbrink et al. 1984); strain Ip90 of B. garinii , a tick isolate from the Asian Russia (Kryuchechnikov et al. 1988); strain B. burgdorferi B313, a mutant of B. burgdorferi B31 lacking OspA and OspB (Sadziene et al. 1993). Also used were three relapsing fever borreliae species, B. hermsii, B. crocidurae, and B. hispanica, and B. anserina, the causative agent of avian borreliosis. Borreliae were grown in BSK II medium (Barbour 1984) and the cells were harvested in late-log phase by centrifugation at 5.000 rpm for 20 min. The Escherichia coli strains Dh5α and BL21 were used for transformation with the recombinant plasmids in, respective¬ ly, DNA cloning and gene expression experiments. E. coli strains were grown in Luria broth medium (Gibco BRL, Gait- hersburg, MD) supplemented, when required, with carbenicillin (Sigma, St. Louis, MO) at 50 μg/ml. EXAMPLE 1. Preparation of Borrelia proteins, sodium dodecyl sulphate-po- lyacrylamide gel electrophoresis (SDS-PAGE) , and Western blot. 1.1 Preparation of Borrelia proteins. For the whole-cell protein preparations, bacteria harvested from 200 ml of BSK II medium were washed twice with phos¬ phate-buffered saline-5mM MgCl 2/ (PBS-Mg) . The pellet was suspended in 2 ml of PBS, sonicated and the supernatant was collected after centrifugation at 10,000 rpm for 30 min. In some experiments whole-cell lysate was obtained by boiling washed bacteria for 3 min in SDS-PAGE sample buffer. The subcellular fraction of borreliae outer membrane compo¬ nents (designated Fraction B) was prepared as described elsewhere (WO 90/04411) . Briefly, cells harvested from 1.5 1 of the culture were washed three times with 10 mM Tris-HCl (pH 7.4) , 150 mM NaCI and 5 mM MgCl 2 . (TSM buffer) . Octyl-jS- D-glucopyranoside (OGP) (Sigma St. Louis, MO) was added to a final concentration of 2% in 10 ml TSM buffer and the suspen¬ sion was incubated at 37°C for 60 min. The cell lysate was centrifuged and the supernatant was incubated at 56°C for 30 min. The precipitate was removed by centrifugation at 20,000 rpm for 30 min at 37°C, and the supernatant was dialysed against water at 4°C for 2 days. The precipitate (Fraction B) formed in the dialysis bag was recovered by centrifugation at 20,000 rpm for 30 min at 25°C. 1.2 Separation of proteins by SDS-PAGE. Bacterial proteins were separated by 12.5% SDS-PAGE essen¬ tially according to Laemmli (1970) . Subsequently, gels were either stained with Coomassie Blue R-250 (CB) (Sigma, St Louis, MO) or were subjected to Western blotting. 1.3 Western blotting. The proteins were transferred to Immobilon-P membrane (Milli- pore, Bedford, MA) by electroblotting at 0.8 mA/cm 2 for 1 h. The nonspecific binding was blocked by immersing the filter for 2 h into 5% bovine serum albumin (BSA) (Sigma, St. Louis, MO) in PBS, containing 0.05% Tween-20 (PBS-T) . Primary or secondary antibodies were diluted with 2.5% BSA in PBS-T, and both incubations of the filter for 1 h was followed by was¬ hing in PBS-T. In a developing reaction the substrate for the alkaline phosphatase conjugate was 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma, St. Louis, MO) . EXAMPLE 2. Preparation of antiserum against 66 kDa. 2.1 Purification of 66 kDa The 66 kDa protein was purified by 12.5% SDS-PAGE of Fraction B obtained from the B. garinii IP90 spirochaetes. The appro- priate band was visualized by staining the gel with 0.05% CB in water without fixation in MeOH and Acetic acid. The pro¬ tein band contained approximately 100 μg of 66 kDa. 2.2 Immunization of rabbits. Approximately 100 μg of the 66 kDa protein prepared as described above was homogenised and used in each of four immunizations of one rabbit performed in one and two (for the last immunization) months intervals. Seven serum samples were obtained during a 5 months period, and serum was diluted 1:1,000 when used for Western blot analysis. EXAMPLE 3. Cell surface proteolysis of Borrelia cells. 3.1 Protease treatment of borreliae cells. Cell surface proteolysis of B. afzelii ACAI cells was con¬ ducted as previously described (Barbour et al. 1984) . Brief¬ ly, washed spirochaetes were resuspended in PBS-Mg at a concentration of 2 x 10 9 cells/ml. To 950 μl of the cell suspension was added 50 μl of one of the following: distilled water, proteinase K (Sigma, St Louis, Mo) (4 mg/ml in water) or trypsin (Gibco BRL, Gaithesburg, MD) (1 mg/ml in 10 "3 M HCI) . After incubation for 40 min at 20°C the proteolytic treatment was stopped by the addition of 10 μl from a so- lution of the peptidase inhibitor phenylmethylsulfonyl fluor¬ ide (PMSF) (Sigma, St. Louis, MO) (50 mg of PMSF per 1 ml of isopropanol) , and the cells were centrifuged and washed twice with PBS-Mg. The pellets were resuspended in TSM buffer. One- third of the cell suspension of each preparation was sub- jected to the whole cell protein extraction by boiling in SDS-PAGE sample buffer. The remaining part of the suspensions were used to prepare the subcellular fraction of the borreli- al outer membrane components, Fraction B, as described above. 3.2 Analysis of the protease treated Borrelia cells. The SDS-PAGE result of the protease treated B. afzelii ACAI cells is presented in Fig. l. As seen in the CB stained protein profiles of the whole-cell lysates (Fig. IA) , pro¬ teinase K affected considerably the minor protein with an apparent molecular weight of 66 kDa. The protein composition of the subcellular fractions of outer membrane components (Fraction B) recovered from protease treated and untreated spirochaetes, was also investigated (Fig. IB) . The 66 kDa protein was shown to constitute a substantial part of the Fraction B, obtained from the protease untreated cells. In the Fraction B derived from the spirochaetes proteolysed with trypsin or proteinase K, the 66 kDa protein was, respective¬ ly, reduced in amount or entirely absent. The finding that protease treatment reduces the amount of the 66 kDa protein clearly shows that the 66 kDa protein is surface exposed, and most probably associated with the outer membrane of the Borrelia. EXAMPLE 4. Expression of the 66 kDa protein in different Borrelia spe¬ cies 4.1 SDS-PAGE analysis. The CB stained SDS-PAGE of the whole-cell protein prepara¬ tions of Lyme disease borreliae and other Borrelia species is shown in Fig. 2A. The 66 kDa protein was present in the whole-cell preparation of B. burgdorferi B31, B. afzelii ACAI, and B. garinii Ip90. The PAGE revealed no major diffe- rences among the borrelial strains in respect of either apparent molecular weight or expression level of the 66 kDa protein. In the analogous preparations of B. hermsii , B. crocidurae, and B. anserina no visible band corresponding to the 66 kDa protein was detectable. In addition to being present in fraction B from B. afzelii ACAI (cf. example 6), the 66 kDa protein was recovered also in the Fraction B of B. burgdorferi B31 and B. garinii Ip90, however, it was absent in the Fraction B obtained from B. crocidurae and B. hispani ¬ ca (data not shown) . 4.2 Western blotting. In Western blot analysis (Fig. 2B) , the 66 kDa protein of B. burgdorferi B31, B. afzelii ACAI, and B. garinii Ip90 reacted similarly with the rabbit antiserum, raised against the 66 kDa protein of the latter strain. There was no apparent reactivity of the antiserum with B. hermsii , B. crocidurae, B. anserina (Fig. 2B) , and B. hispanica (data not shown) proteins. The rabbit antiserum raised against the 66 kDa protein of B. garinii Ip90, in Western blots reacted equally against 66 kDa protein of B. burgdorferi B31 and B. Afzelii ACAI indicating that 66 kDa protein is highly conserved among Lyme disease associated borreliae. These data indicate that 66 kDa protein is unique among Lyme disease borreliae. Conversely, it was shown recently that the ospC gene homologues and OspC-related proteins are present in Borrelia species not associated with Lyme borreliosis (Marco¬ ni et al. 1993) . EXAMPLE 5. In vitro growth inhibition of borreliae by antibodies against the 66 kDa protein The in vitro growth inhibition of borreliae by antibodies against the 66 kDa protein was performed as described else¬ where (Sadziene et al. 1993) . Briefly, borreliae were grown to the concentration of approximately 10 8 cells/ml, as counted in a Petroff-Hauser chamber by phase-contrast micro¬ scopy. The concentration of the cells was adjusted to 2 x 10 7 cells/ml by adding fresh medium. 100 μl of the diluted cul¬ ture was placed in flat-bottomed wells of 96-well microtiter plates, and the rabbit antiserum against the 66 kDa protein prepared as described above diluted twofold in BSK II medium was added. The serum obtained from the same rabbit before the immunization was used for negative control. The plates were then incubated for 72 h at 34°C, and the inhibitory titer of the antiserum was evaluated by comparing the cell counts with the negative control. Complement was inactivated in all sera by heat-treatment at 56°C for 30 min. The effect of the rabbit monospecific polyclonal anti-66 kDa protein antibodies on in vitro growth of borreliae was exam¬ ined. The growth inhibition, occurring after adding the antibodies into the culture, resulted in reduced cell counts and appearing of mainly not motile spirochaetes, carrying large surface blebs. For all Lyme disease associated Borrelia strains included in the assay, in vi tro growth was inhibited by the antibodies against the 66 kDa protein. The inhibitory titer of the antiserum was 1:8, 1:4,and 1:4 for, respective- ly, B . burgdorferi B31, B. afzelii ACAI, and B. garinii Ip90. The inhibitory titer of the antiserum was 1:16 when the growth inhibition test was performed on the B. burgdorferi B31 mutant B313 lacking OspA and OspB. The antiserum raised against the 66 kDa protein of B. garinii Ip90 was able to inhibit the in vitro growth of all three Lyme disease associated Borrelia strains used in the assay. This further indicates that the 66 kDa protein is highly conserved among Lyme disease associated borreliae and hence is an antigen being a potential vaccine candidate and a diagnostic tool. EXAMPLE 6. Isolation and N-terminal amino acid sequencing of the 66 kDa protein. 6.1 Amino acid sequencing. The Fraction B of strain ACAI of B. afzelii was electrophore- sed and transferred to Fluorotrans transfer membrane (Pall, East Hills, NY) . The protein bands were visualized by stai¬ ning the membrane with 0.1% CB in 50% methanol. After destai- ning with 50% methanol, the 66 kDa protein band was cut from the membrane and N-terminal amino acid sequence analysis was performed on a 477A sequenator (Applied Biosystems, Foster City, CA) at Umea University. N-terminal amino acid sequence of the 66 kDa protein, recovered from the Fraction B of B. afzelii ACAI, is pre¬ sented, SEQ ID NO: 1. 6.2 Design of oligonucleotide probe. The sequence of the 8 amino acid fragment was used to design the oligonucleotide sequence, SEQ ID NO: 2. The choice of A and T nucleotides in the wobble positions was reasoned by the preferential utilisation of codons with A and T nucleotides in Borrelia genome (Burman et al. 1990) . EXAMPLE 7. Preparation of Bb DNA libraries. 7.1 Extraction of DNA. The spirochaetes harvested from 400 ml of culture, were washed twice with 50 mM Tris-HCl (pH=7.4) and resuspended in 10 ml of buffer containing 50 mM Tris-HCl (pH=7.4), 25% sucrose, and 50 mM EDTA. The cells were lysed by adding SDS to a final concentration of 2%, lysozyme (Sigma, St. Louis, MO) (1.5 mg/ml), proteinase K (Sigma, St. Louis, MO) (0.1 mg/ml), and RNAase A (Sigma, St Louis, MO) (10 μg/ml). The DNA was extracted with buffered phenol and ethanol precipi¬ tated. 7.2 Construction of a genomic DNA library. Restriction enzymes were obtained from Boehringer, Mannheim, Germany. 100 ng of borrelial genomic DNA prepared as described above was completely digested using EcoRI , Xbal, and PstI restriction endonucleases separately or in combina¬ tion. For the partial digestions, 1 U of Hindlll restriction endonuclease was incubated with 100 ng of genomic DNA for 10 min. at 37°C. Twenty nanograms of appropriately digested pUC18 (Pharmacia, Uppsala, Sweden) vector was used for ligations. EXAMPLE 8. Cloning and sequencing of the gene encoding the 66 kDa pro¬ tein. 8.1 Screening of genomic library prepared from B. garinii Ip90. The recombinant plasmids were transformed into competent E. coli Dh5θ! cells. Initially, B. garinii Ip90 Hindlll digested genomic DNA library was screened with the designed degene¬ rated oligonucleotide probe: 5' -GAA AAA GAT ATW TTT AAA ATW AAT-3' (SEQ ID NO: 2) synthesized on the basis of the N-terminal amino acid sequence of the 66 kDa protein obtained in Example 5 (corres¬ ponding to amino acids 6-13) . A recombinant plasmid desig¬ nated (pJB-100) recovered from one positive E. coli Dh5o. clone was sequenced. A gene fragment containing 592 bp inclu¬ ding the ATG start codon followed by a discontinued open reading frame (ORF) was identified. The full-length 66 kDa protein gene was retrieved from B. garinii Ip90 EcoRI/Xbal genomic DNA library in the same vector by probing with the radiolabelled 66 kDa protein gene fragment within BamHI and Hindlll restriction sites on pJB-100. A recombinant plasmid designated pJB-101 derived from another positive E. coli Dh5o; clone, harboured a 4.1 kb DNA insert. The sequencing of the 66 kDa protein gene proceeded until the TAA stop codon was detected. The clones were sequenced by the dideoxy chain termination method, using /γ- 35 S/dATP (Amersham, Buckinghamshire, UK) and the Pharmacia T7 sequencing kit according to the procedure described by the manufacturer (Pharmacia, Uppsala, Sweden) . The sequence fragments were assembled using the GENEUS software for VAX computer. 8.2 Screening of genomic library prepared from B. burgdorferi B31 and B. afzelii ACAI. The 592 bp 66 kDa protein gene fragment within BamHI and Hindlll restriction sites was recovered from plasmid prepara¬ tion and radiolabelled by random primer technique. It was then used to screen B. burgdorferi B31 and B. afzelii ACAI genomic DNA libraries. A recombinant plasmid designated pJB- 102 was found to harbour a 2.4 kb insert comprising a segment of the 66 kDa protein gene from B. burgdorferi B31 lacking the coding sequence for the signal peptide and a recombinant plasmid designated pJB-105 was found to harbour a 1.5 kb insert comprising the DNA encoding the initial Met and the following 17 amino acids. Together with the DNA sequence found in pJB-102, the full sequence encoding the 66 kDa protein from B31 was then established. A recombinant plasmid designated pJB-104 was found to harbour a 10 kb insert com¬ prising the complete 66 kDa protein gene from B. afzelii ACAI. Both strands of the full-length genes coding for the 66 kDa protein in different Lyme disease Borrelia species were sequenced as described above. 8.3 Sequence analysis. Sequence analyses were performed using the University of Wisconsin GCG Sequence Analysis Software Version 7.2 for VAX computer, MacVector (IBI, Newhaven CT) for Macintosh com¬ puters, and PC-Gene (Genofit) for XT/AT personal computers. Search in protein sequence databases was performed at the NCBI using the BLAST network service. The nucleotide sequence of the 66 kDa protein gene of B. burgdorferi B31, B. afzelii ACAI, B. garinii Ip90, as well as neighbouring regions are shown in SEQ ID NO: 3, SEQ ID NO: 5 SEQ ID NO: 7, and SEQ ID NO: 13. The ATG start codon was followed by an ORF of 1857, 1860 and 1866 nucleotides for strains B31, ACAI, and Ip90, respectively. A consensus ribo- somal binding site (RBS) , GGAAGG, could be detected upstream of the start codon. Further upstream, sequences closely resembling the "-10"-region (-TATTAT-) and the "-35"-region (-TTGAAT-) were located at positions -185 and -209, respec¬ tively. The B31 clone did not contain the ATG start codon and the sequence coding for the signal sequence, but contained the sequence coding for the complete processed protein. The 66 kDa protein gene terminated at a TAA triplet, which was followed by AT rich region containing putative stem and loop structures. The deduced amino acid sequence of the 66 kDa protein of B. burgdorferi B31, B. afzelii ACAI and B. garinii Ip90 is presented in SEQ ID NO: 4 and SEQ ID NO: 14, SEQ ID NO: 6 and SEQ ID NO: 8, respectively. The computer analysis predicted the potential leader peptidase I cleavage site between amino acid residues at position 21, and the N-terminal peak was found on the hydrophobicity plot (data not shown) in all three cases. The processed 66 kDa protein from the strains B31, ACAI and Ip90 consisted of, respectively, 597, 598 and 600 amino acids with a calculated molecular weight of 65,802 kDa, 65,796 kDa and 65.944 kDa. The amino acid sequence of the 66 kDa protein from B. burgdorferi B31 was 92.7% and 91.5% identical to the sequences from, respectively, B. afzelii ACAI and B. garinii Ip90. When compared with each other, the two latter strains showed 93.9% identity. The level of similarity and identity between the deduced amino acid sequence of the 66 kDa protein from different borrelia strains further shows that this protein can be useful as a vaccine against Lyme disease as well as a target for diagnostic use. 8.4 Antigenicity plot Potential antigenic regions of the deduced amino acid sequences of the 66 kDa proteins from Borrelia burgdorferi sensu stricto B31, Borrelia afzelii ACAI, and Borrelia gari ¬ nii IP90 were identified by calculation of the antigenic index using the algorithm of Jameson and Wolf (1988) . The results are shown in Fig. 5. Proposed epitopic regions having a high antigenic index are e.g. the amino acid sequences corresponding to positions 175-190, 285-305, 365-385, and 465-490. The 66 kDa proteins were examined for the sequence similarity to other known proteins in database libraries. There were no other sequences related significantly to the 66 kDa proteins. EXAMPLE 9 Localization of the 66 kDa protein gene. 9.1 Separation of DNA by pulse-field agarose gel electropho- resis. For the pulse-field AGE, the genomic DNA prepared from B. Jburgrdorferi B31, B. afzelii ACAI and B. garinii Ip90 was recovered in 1% agarose blocks as previously described (Fer- dows and Barbour, 1989) . One-dimensional and pulse-field AGE were performed in 0.7% and 1% agarose, respectively, in TBE buffer. For the pulse-field AGE pulse times were 1 s for 9 h and then 5 s for 9 h at a constant current of 180 mA. 9.2 Southern blotting. Following depurination, denaturation and neutralization of the gels, the DNA was transferred to Hybond-N membrane (Amersham, Buckinghamshire, UK) by the method of Southern (Sambrook et al. 1989), and cross-linked with UV light. Filters were prehybridized and hybridized for, respectively, 1 h and 4 h, and washed. The temperature was 37°C for probing with degenerate oligonucleotide, end-labelled with /γ- 32 P/dATP (Amersham, Buckinghamshire, UK) , and 55°C for probing with DNA fragment, radiolabelled by random primer technique (Amersham, Buckinghamshire, UK) . The hybridizing band corresponded to the position of the 1 Mbp linear chromosome of Lyme disease borreliae, cf. Fig. 3. There was no significant signs of hybridization with the DNA from relapsing fever Borrelia species, B. hermsii , B. croci ¬ durae, and B. hispanica (data not shown) . Furthermore, the 66 kDa protein gene being localized to the chromosome of borreliae shows a higher degree of conservation among Lyme disease associated borreliae contrary to the plasmid-encoded major outer surface proteins ' A, B, and C which exhibit a significant species and strain dependent genetic and antigenic polymorphism (Barbour 1986, Jonsson et al. 1992, Wilske et al. 1993). EXAMPLE 10. Expression of the 66 kDa protein from B. burgdorferi B31 in E. coli . Two oligonucleotide primers, 5' -GCA ATA TTT GCT GCA GCA GAT-3' SEQ ID NO: 11 5' -GGC CTA AAG GAA TTC TTT TGC-3' SEQ ID NO: 12 were designed to anneal to the 5' end (devoid of the leader peptide sequence) and the 3' end of the 66 kDa protein gene from B. burgdorferi B31. The primers contained, respectively, PstI and EcoRI restriction sites, and were used to amplify the 66 kDa protein gene in the PCR. PCR amplification was performed using Ampli-Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) . The PCR product was then treated with the mentioned restriction enzymes, purified by AGA and ligated into the T7 based expression vector pRSET (Invitrogen, San Diego, CA) . The recombinant plasmid was then used to trans¬ form E. coli BL21 cells. E. coli BL21 cells containing the insert were grown and induced with by adding isopropyl -β-D- thiogalactopyranoside (IPTG) (Sigma, St. Louis, MO) to a final concentration of 1 mM to express the introduced 66 kDa protein gene. The 66 kDa protein gene product was subsequently identified by SDS-PAGE and Western blot with rabbit antiserum raised against the 66 kDa protein. Fig. 4 show the southern blot. REFERENCES Adam T, Gassmann GS, Rasiah C, Gδbel UB. 1991. Phenotypic and genotypic analysis of Borrelia burgdorferi isolates from various sources. Infection and Immunity, 59: 2579-2585. Adelamn et al. 1983. DNA, 2: 183. Anderson JF, Magnarelli LA, McAnich JB. 1988. Journal of Clinical Microbiology, 26: 2209-2212. Arimitsu Y, Takashima I, Yoshii Z, Higashi Y, Kameyama S, Mizuguchi J. 1991. Journal of Infectious Diseases, 163: 682- 683. Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti J-C, Assous M, Grimont PAD. 1992. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. International Journal of Systematic Bacteriology, 42: 378-383. Barbour AG, Burgdorfer W, Grunwaldt Ξ, Steere AC. 1983. Antibodies of patients with Lyme disease to components of the Jxodes damini spirochete. Journal of Clinical Investigation, 72: 504-515. Barbour AG, Tessier SL, Hayes SF. 1984. Variation in a major surface protein of Lyme disease spirochetes. Infection and Immunity, 45: 94-100. Barbour AG. 1984. Immunochemical analysis of Lyme disease spirochetes. The Yale Journal of Biology and Medicine, 57: 581-586. Barbour AG. 1986. Polymorphisms of major surface proteins of Borrelia burgdorferi . Zbl Bakt Hyg, 263: 83-91. Barbour AG. 1988. Journal of Clinical Microbiology, 26: 475- 478. Barthold SW, Bockenstedt LK. 1993. Passive immunizing acti¬ vity of sera from mice infected with Borrelia burgdorferi . Infection and Immunity, 61: 4696-4702. Beaucage SL, Caruthers MM et al. 1981. Tetrahedron Letters, 22: 1859-1862. Bergstrom S, Sjδstedt A, Dotevall L, Kaijser B, Ekstrand-Ham- marstrδm B, Wallberg C, Skogman G, Barbour AG. 1991. Diag¬ nosis of Lyme borreliosis by an enzyme immunoassay detecting immunoglobulin G reactive to purified Borrelia burgdorferi cell components. European Journal of Clinical Microbiology and Infectious Diseases, 10: 422-427. Bolivar et al. Gene, 2: 95. Brucebauer HR, Preac-Mursic V, Fuchs R, Wilske B. 1992. Cross reactive proteins of Borrelia burgdorferi . European Journal of Infectious Diseases, 3: 224-232. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. 1983 Lyme disease - a tick borne spirochetosis? Science, 216: 1317-1319. Burman N, Bergstrom S, Restrepo BI, Barbour AG. 1990. The variable antigens Vmp7 and Vmp21 of the relapsing fever bacterium Borrelia hermsii are structurally analogous to the VSG proteins of the African trypanosome. Molecular Microbio¬ logy, 4: 1715-1726. Canica MM, Nato F, duMerle L, Mazie JC, Baranton G, Postic D. 1993. Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifesta- tions of Lyme borreliosis. Scandinavian Journal of Infectious Diseases, 25: 441-448. Chang et al. 1978. Nature, 275: 617-624. Coleman JL, Benach JL. 1987. Isolation of antigenic compo¬ nents from the Lyme disease spirochete: their role in early diagnosis. Journal of Infectious Diseases, 155: 756-765. Craft JE, Grodzicki RL, Steere AC. 1984. Journal of Infec¬ tious Diseases, 149: 789-795. Crea et al. 1978. Proceeding of the National Academy of Sciences USA, 75: 5765. Dressier F, Whalen JA, Reinhardt BN, Steere AC. 1993. Western blotting in the serodiagnosis of Lyme disease. The Journal of Infectious Diseases, 167: 392-400. Eichenlaub R. 1979. Journal of Bacteriology, 138: 559-566. Erdile LF, Brandt M-N, Warakomski DJ, Westrack GJ, Sadziene A, Barbour AG, Mays JP. 1993. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infection and Immunity, 61: 81-90. Ferdows MS, Barbour AG. 1989. Megabase-sized linear DNA in the bacterium Borrelia burgdorferi , the Lyme disease agent. Proceedings of National Academy of Science, 86: 5969-5973. Fiers et al. 1978. Nature, 273: 113. Fikrig E, Barthold SW, Marcantonio N, DePonte K, Kantor FS, Flavell RA. 1992. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infection and Immunity, 60: 657-661. Fikrig E, Barthold SW, Persing DΞ, Sun X, Kantor FS, Flavell RA. 1992. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. Journal of Immunology, 148: 2256-2260. Gassmann GS, Jacobs E, Deutzmann R, Gδbel UE. 1991. Analysis of fla gene of Borrelia burgdorferi GeHo and antigenic cha¬ racterization of its gene product. Journal of Bacteriology, 173: 1452-1459. Godman JL, Jarkovich P, Kramber JM, Johnson RC. 1991. Infec¬ tion and Immunity, 59: 269-278. Goeddel et al. 1979. Nature, 281: 544. Grodzicki RL, Steere AC. 1988. Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using diffe¬ rent antigen preparations for diagnosing early Lyme disease. Journal of Infectious Diseases, 157: 790-797. Hess et al. 1969. Advances in Enzyme Regulation, 7: 149-166. Hitzeman et al. 1980. Journal of Biological Chemistry, 25: 12073-12080. Holland et al. 1978. Biochemistry, 17: 4900. Hopp TP, Woods KR. 1981. Proceedings of the National Academy of Science USA, 78: 3824-3828. Itakura et al. 1977. Science, 198: 1056. Jameson BA, Wolf H. 1988. Computer Application in the biosciences, 4: 181-186 Jones. 1977. Genetics, 85: 23-33. Jonsson M, Noppa L,. Barbour AG, Bergstrom S. 1992. Heterogeneity of outer membrane proteins in Borrelia burgdor¬ feri : comparison of osp operons of three isolates of differ- rent geographic origins. Infection and Immunity, 60: 1845- 1853. Kimgsman et al. 1979. Gene, 7: 141. Kryuchechnikov VN, Korenberg El, Scherbakov SV, Kovalevsky YV, Levin ML. 1988. Identification of Borrelia isolated in the USSR from Jxodes persulcatus schulze ticks. Journal of Microbiology, Epidemiology and Immunobiology, 12: 41-44. Kyte J, Doolittle RF. 1982. Journal of Molecular Biology, 157: 105-132. Laemmli UK. 1970. Nature 227:680-685 Lebech AM, Hlndersson P, Vuust J, Hansen KJ. 1991. Journal of Clinical Microbiology, 29: 731-737. Luft BJ, Jiang W, Munoz P, Dattwyler RJ Gorevic PD. 1989. Biochemical and immunological characterization of the surface proteins of Borrelia burgdorferi . Infection and Immunity, 57: 3637-3645. Luft BJ, Gorevic PD, Jiang W, Munoz P, Dattwyler RJ. 1991. Immunologic and structural characterization of the dominant 66- to 73-kDa antigens of Borrelia burgdorferi . Journal of Immunology, 146: 2776-2782. Ma B, Christen B, Leung D, Vigo-Pelfrey C. 1992. Serodiagnosis of Lyme borreliosis by Western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi . Journal of Clinical Microbiology, 30: 370-376. Magnarelli LA., Anderson JF, BarbourAG. 1989. Enzyme-linked immunosorbent assays for Lyme disease: reactivity of subunits of Borrelia burgdorferi . Cross-reactivity in serologic tests for Lyme disease and other spirochetal infections. Journal of Infectious Diseases, 159: 43-49. Magnarelli LA., Anderson JF, Johnson RC. 1987. Cross-reacti¬ vity in serologic tests for Lyme disease and other spiroche¬ tal infections. Journal of Infectious Diseases, 156: 183-188. Magnarelli LA., iller JN, Anderson JF, Riviere GR. 1990. Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease. Journal of Clinical Micro¬ biology, 28: 1276-1279. Marconi RT, Garon CF. 1992. Phylogenetic analysis of the genus Borrelia : a comparison of North American and European isolates of Borrelia burgdorferi . Journal of Bacteriology, 174: 241-244. Marconi RT, Konkel ME, Garon CF. 1993. Variability of osp genes and gene products among species of Lyme disease spiro¬ chetes. Infection and Immunity, 61: 2611-2617. Marconi RT, Samuels DS, Schwan TG, Garon CF. 1993. Identifi¬ cation of a protein in several Borrelia species which is related to OspC of Lyme disease spirochetes. Journal of Clinical Microbiology, 31: 2577-2583. Messing et al. 1981. Third Cleveland Symposium on Macromolecules and Recombinant DNA, Ed. A Walton, Elsevier, Amsterdam. Nielsen P E et al . , 1991, Science 254: 1497-1500. Norris SJ, Carter CJ, Howell JK, Barbour AG. 1992. Low-passa- ge-associated proteins of Borrelia burgdorferi B31: Charac¬ terization and molecular cloning of OspD, a surface exposed, plasmid-encoded lipoprotein. Infection and Immunity, 60: 4662-4672. Norton Hughes CA, Engstrom SM, Coleman LA, Kodner CB, Johnson RC. 1993. Protective immunity is induced by a Borrelia burg¬ dorferi mutant that lacks OspA and Os.τ3B. Infection and Immun¬ ity, 61: 5115-5122. Olsen B, Jaenson TGT, Noppa L, Bunikis J, Bergstrom S. 1993. A Lyme borreliosis cycle in seabirds and Ixodes uriae ticks. Nature, 362: 340-342. Preac-Mursic V, Wilske B, Patsouris E, Jauris S, Will G, Soutschek Ξ, Reinhardt S, Lehnert G, Klockmann U, Mehraein P. 1992. Active immunization with pC protein of Borrelia burg¬ dorferi protects gerbils against Borrelia burgdorferi infec- tion. Infection, 20: 342-349. Rahn DW, Malawista SE. 1991. Annals of Internal Medicine, 114: 472-481. Raoult D, Hechemy KE, Baranton G. 1989. Crossreaction with Borrelia burgdorferi antigen of sera from patients with human immunodeficiency virus infection, syphilis, and leptospirosis. Journal of Clinical Microbiology, 27: 2152- 2155. Rosa PA, Schwan TG. 1989. Journal of infectious diseases, 160: 1018-1029. Sadziene A, Thompson PA, Barbour AG. 1993. In vitro inhibi¬ tion of Borrelia burgdorferi growth by antibodies. Journal of Infectious Diseases, 167: 165-172. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Schmid GP. 1985. Reviews of infectious diseases, 7: 41-49. Shanafelt MC, Hinderson P, Soderberg C, Mensi N, Turck CW, Webb D, Yssel H, Peltz G. 1991. Journal of Immunology, 146: 3985-3992. Siebwenlist et al. 1980. Cell, 20: 269. Simon MM, Schaible UE, Wallich R, Kramer MD. 1991. A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease. Immunology Today, 12: 11-16. Simpson WJ, Schrumpf ME, Schwan TG. 1990. Reactivity of human Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia burgdorferi . Journal of Clinical Microbiology, 28: 1329-1337. Steere AC, Malawista SE, Syndman DR. 1977. Arthritis and rheumatism, 20: 7-17. Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. 1986. Journal of Infectious Diseases, 154: 295-300. Steere AC. 1989. Lyme disease. New England Journal of Medi¬ cine, 321: 586-596. Stinchomb et al. 1979. Nature 282: 39. Theisen M, Frederiksen B, Lebech A-M, Vuust J, Hansen K. 1993. Polymorphism in ospC gene of Borrelia burgdorferi and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. Journal of Clinical Microbiology, 31: 2570-2576. Tschemper et al. 1980. Gene, 10: 157. Ulmer JB et al. 1993. Curr. Opin. Invest. Drugs, 2: 983-989. Wallich R, Moter SE, Simon MM, Ebnet K, Heiberger A, Kramer MD. 1990. Infection and Immunity, 58: 1711-1719. Wilske B, Preac-Mursic V, Jauris S, Hof an A, Pradel I, Soutschek E, Schwab E, Will G, Wannei G. 1993. Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi . Infection and Immunity, 61: 2182-2191. Wilske B, Preac-Mursic V, Schierz G, Busch KV. 1986. Immuno- chemical and immunological analysis of European Borrelia burgdorferi strains. Zbl Bakt Hyg, 263: 92-102. Zingg BC, Anderson JF, Johnson RC, LeFebvre RB. 1993. Com¬ parative analysis of genetic variability among Borrelia burgdorferi isolates from Europe and the United States by restriction enzyme analysis, gene restriction fragment length polymorphism, and pulse-field gel electrophoresis. Journal of Clinical Microbiology, 31: 3115-3122. Asbrink E, Hovmark A, Hederstedt B. 1984. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Dermatologica et Venereologica, 64: 506-512. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Symbicom AB (B) STREET: c/o Astra Hassle AB, Tvistevagen 48 (C) CITY: Umea (E) COUNTRY: Sweden (F) POSTAL CODE (ZIP) : S-907 36 (ii) TITLE OF INVENTION: New 66kDa antigen from Borrelia (iii) NUMBER OF SEQUENCES: 14 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrelia afzelii (B) STRAIN: ACAI (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Ala Asp Ala Leu Lys Glu Lys Asp lie Phe Lys lie Asn Pro Gly lie 1 5 10 15 Pro Asp Phe Gly 20 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: GAAAAAGATA TWTTTAAAAT WAAT 24 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2075 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrelia burgdorferi (B) STRAIN: B31 (vii) IMMEDIATE SOURCE: (B) CLONE: p B-102 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:109..1914 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION:109..120 (D) OTHER INFORMATION:/partial /label= partial (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION:121..1911 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GCTGGCGGAA GGGGGATGTG CTGCAAGGCG ATTAAGTTGG GTAACGCCAG GGTTTTCCCA 60 GTCACGACGT TGTAAAACGA CGGCCAGTGC CAAGCTTGCA TGCCTGCA GCA ATA TTT 117 Ala He Phe -4 GCA GCA GAC GCA TTA AAG GAA AAA GAT ATA TTT AAA ATA AAC CCA TGG 165 Ala Ala Asp Ala Leu Lys Glu Lys Asp He Phe Lys He Asn Pro Trp 1 5 10 15 ATG CCA ACA TTT GGA TTT GAA AAC ACA AGT GAA TTC AGA TTA GAT ATG 213 Met Pro Thr Phe Gly Phe Glu Asn Thr Ser Glu Phe Arg Leu Asp Met 20 25 30 GAC GAG CTT GTT CCT GGG TTT GAA AAC AAA AGC AAA ATT ACC ATT AAG 261 Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser Lys He Thr He Lys 35 40 45 CTT AAA CCA TTT GAA GCT AAT CCC GAA TTA GGC AAA GAC GAT CCA TTC 309 Leu Lys Pro Phe Glu Ala Asn Pro Glu Leu Gly Lys Asp Asp Pro Phe 50 55 60 TCA GCT TAC ATT AAG GTA GAA GAT CTT GCA CTA AAA GCG GAA GGC AAA 357 Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu Lys Ala Glu Gly Lys 65 70 75 AAA GGC GAT CAA TTT AAA ATT GAC GTG GGA GAT ATT ACA GCC CAA ATC 405 Lys Gly Asp Gin Phe Lys He Asp Val Gly Asp He Thr Ala Gin He 80 85 90 95 AAT ATG TAC GAT TTT TTT ATT AAA ATA AGT ACT ATG ACA GAT TTT GAC 453 Asn Met Tyr Asp Phe Phe He Lys He Ser Thr Met Thr Asp Phe Asp 100 105 110 TTT AAT AAA GAG TCT TTA TTT AGT TTT GCA CCT ATG ACT GGA TTT AAA 501 Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro Met Thr Gly Phe Lys 115 120 125 AGC ACT TAC TAT GGA TTC CCA AGC AAT GAT AGG GCA GTA AGA GGG ACA 549 Ser Thr Tyr Tyr Gly Phe Pro Ser Asn Asp Arg Ala Val Arg Gly Thr 130 135 140 ATT CTT GCA AGA GGT ACT TCT AAA AAC ATA GGA ACA ATT CAG CTG GGA 597 He Leu Ala Arg Gly Thr Ser Lys Asn He Gly Thr He Gin Leu Gly 145 150 155 TAC AAA CTC CCA AAA CTC GAC CTT ACA TTT GCA ATA GGG GGA ACA GGC 645 Tyr Lys Leu Pro Lys Leu Asp Leu Thr Phe Ala He Gly Gly Thr Gly 160 165 170 175 ACG GGT AAC AGA AAT CAA GAG AAT GAC AAA GAC ACT CCA TAC AAT AAA 693 Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp Thr Pro Tyr Asn Lys 180 185 190 ACA TAT CAA GGA ATC CTT TAT GGA ATT CAA GCA ACA TGG AAA CCA ATA 741 Thr Tyr Gin Gly He Leu Tyr Gly He Gin Ala Thr Trp Lys Pro He 195 200 205 AAA AAT CTA CTT GAT CAA AAC GAA GAT ACT AAA TCT GTA ATT GCA GAA 789 Lys Asn Leu Leu Asp Gin Asn Glu Asp Thr Lys Ser Val He Ala Glu 210 215 220 ACA CCT TTT GAA TTA AAT TTT GGC TTG TCA GGA GCC TAT GGA AAC GAG 837 Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly Ala Tyr Gly Asn Glu 225 230 235 ACA TTC AAT AAT TCA TCA ATA ACA TAC TCT TTA AAA GAT AAA TCC GTA 885 Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu Lys Asp Lys Ser Val 240 245 250 255 GTT GGC AAC GAT TTA TTG AGC CCA ACT TTA TCA AAT TCT GCA ATT TTA 933 Val Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser Asn Ser Ala He Leu 260 265 270 GCA TCT TTT GGA GCT AAA TAT AAG CTT GGA TTA ACA AAA ATA AAC GAT 981 Ala Ser Phe Gly Ala Lys Tyr Lys Leu Gly Leu Thr Lys He Asn Asp 275 280 285 AAA AAT ACC TAT CTT ATT TTG CAA ATG GGA ACT GAT TTT GGA ATA GAT 1029 Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr Asp Phe Gly He Asp 290 295 300 CCT TTT GCA AGC GAT TTT TCT ATA TTT GGA CAC ATC TCA AAA GCA GCG 1077 Pro Phe Ala Ser Asp Phe Ser He Phe Gly His He Ser Lys Ala Ala 305 310 315 AAT TTC AAA AAA GAA ACA CCC TCA GAT CCT AAC AAA AAA GCT GAA ATA 1125 Asn Phe Lys Lys Glu Thr Pro Ser Asp Pro Asn Lys Lys Ala Glu He 320 325 330 335 TTT GAT CCA AAT GGC AAT GCT CTT AAT TTC AGC AAA AAC ACA GAA TTG 1173 Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe Ser Lys Asn Thr Glu Leu 340 345 350 GGC ATT GCA TTT TCA ACA GGA GCA AGT ATA GGT TTT GCT TGG AAT AAA 1221 Gly He Ala Phe Ser Thr Gly Ala Ser He Gly Phe Ala Trp Asn Lys 355 360 365 GAT ACC GGT GAA AAA GAA TCC TGG GCG ATT AAA GGA TCT GAT TCC TAC 1269 Asp Thr Gly Glu Lys Glu Ser Trp Ala He Lys Gly Ser Asp Ser Tyr 370 375 380 AGT ACA AGA CTC TTT GGA GAA CAA GAC AAA AAA TCT GGA GTT GCA TTG 1317 Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys Lys Ser Gly Val Ala Leu 385 390 395 GGA ATA AGC TAT GGA CAA AAC CTT TAC AGA TCT AAA GAT ACA GAA AAA 1365 Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg Ser Lys Asp Thr Glu Lys 400 405 410 415 AGA TTA AAA ACC ATA TCT GAA AAT GCA TTT CAA AGC TTA AAT GTT GAA 1413 Arg Leu Lys Thr He Ser Glu Asn Ala Phe Gin Ser Leu Asn Val Glu 420 425 430 ATT TCA AGC TAT GAA GAC AAC AAA AAA GGG ATT ATA AAT GGA TTA GGA 1461 He Ser Ser Tyr Glu Asp Asn Lys Lys Gly He He Asn Gly Leu Gly 435 440 445 TGG ATA ACA TCT ATC GGT CTT TAC GAT ATT TTA AGA CAA AAA TCT GTA 1509 Trp He Thr Ser He Gly Leu Tyr Asp He Leu Arg Gin Lys Ser Val 450 455 460 GAA AAC TAT CCT ACA ACA ATT TCA AGC ACC ACT GAA AAC AAT CAA ACT 1557 Glu Asn Tyr Pro Thr Thr He Ser Ser Thr Thr Glu Asn Asn Gin Thr 465 470 475 GAA CAA AGT TCA ACA AGC ACA AAG ACC ACA ACC CCT AAT CTG ACA TTT 1605 Glu Gin Ser Ser Thr Ser Thr Lys Thr Thr Thr Pro Asn Leu Thr Phe 480 485 490 495 GAA GAT GCA ATG AAA CTC GGC TTG GCC TTA TAT CTT GAT TAT GCA ATT 1653 Glu Asp Ala Met Lys Leu Gly Leu Ala Leu Tyr Leu Asp Tyr Ala He 500 505 510 CCA ATA GCA TCC ATT TCA ACA GAA GCA TAT GTA GTA CCT TAC ATT GGA 1701 Pro He Ala Ser He Ser Thr Glu Ala Tyr Val Val Pro Tyr He Gly 515 520 525 GCA TAC ATT TTA GGA CCT TCT AAT AAA CTC TCA AGC GAT GCT ACA AAA 1749 Ala Tyr He Leu Gly Pro Ser Asn Lys Leu Ser Ser Asp Ala Thr Lys 530 535 540 ATT TAT TTA AAA ACA GGA CTT AGC CTT GAA AAA CTA ATA AGA TTT ACA 1797 He Tyr Leu Lys Thr Gly Leu Ser Leu Glu Lys Leu He Arg Phe Thr 545 550 555 ACA ATT TCT CTT GGA TGG GAT TCA AAT AAC ATT ATA GAA CTT GCT AAT 1845 Thr He Ser Leu Gly Trp Asp Ser Asn Asn He He Glu Leu Ala Asn 560 565 570 575 AAA AAC ACA AAT AAT GCT GCT ATT GGA AGT GCT TTC TTG CAA TTC AAA 1893 Lys Asn Thr Asn Asn Ala Ala He Gly Ser Ala Phe Leu Gin Phe Lys 580 585 590 ATA GCC TAC AGC GGA AGC TAA CAGCAAAAGA AGGGCTTTGG CCCTTCTTTT 1944 He Ala Tyr Ser Gly Ser * 595 TTATCTTTAA AAACAATTGG GATTACCTTA TATTTCTTTC CTTGCAAATT TTTTCATAAG 2004 CATCTTGAAT TTTTATAAAT TTATCATTTG CATCTTTTTG TCTTACAGGA TCATTTGCAA 2064 ACTTATCAGG A 2075 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 601 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Ala He Phe Ala Ala Asp Ala Leu Lys Glu Lys Asp He Phe Lys He -4 1 5 10 Asn Pro Trp Met Pro Thr Phe Gly Phe Glu Asn Thr Ser Glu Phe Arg 15 20 25 Leu Asp Met Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser Lys He 30 35 40 Thr He Lys Leu Lys Pro Phe Glu Ala Asn Pro Glu Leu Gly Lys Asp 45 50 55 60 Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu Lys Ala 65 70 75 Glu Gly Lys Lys Gly Asp Gin Phe Lys He Asp Val Gly Asp He Thr 80 85 90 Ala Gin He Asn Met Tyr Asp Phe Phe He Lys He Ser Thr Met Thr 95 100 105 Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro Met Thr 110 115 120 Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser Asn Asp Arg Ala Val 125 130 135 140 Arg Gly Thr He Leu Ala Arg Gly Thr Ser Lys Asn He Gly Thr He 145 150 155 Gin Leu Gly Tyr Lys Leu Pro Lys Leu Asp Leu Thr Phe Ala He Gly 160 165 170 Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp Thr Pro 175 180 185 Tyr Asn Lys Thr Tyr Gin Gly He Leu Tyr Gly He Gin Ala Thr Trp 190 195 200 Lys Pro He Lys Asn Leu Leu Asp Gin Asn Glu Asp Thr Lys Ser Val 205 210 215 220 He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly Ala Tyr 225 230 235 Gly Asn Glu Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu Lys Asp 240 245 250 Lys Ser Val Val Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser Asn Ser 255 260 265 Ala He Leu Ala Ser Phe Gly Ala Lys Tyr Lys Leu Gly Leu Thr Lys 270 275 280 He Asn Asp Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr Asp Phe 285 290 295 300 Gly He Asp Pro Phe Ala Ser Asp Phe Ser He Phe Gly His He Ser 305 310 315 Lys Ala Ala Asn Phe Lys Lys Glu Thr Pro Ser Asp Pro Asn Lys Lys 320 325 330 Ala Glu He Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe Ser Lys Asn 335 340 345 Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala Ser He Gly Phe Ala 350 355 360 Trp Asn Lys Asp Thr Gly Glu Lys Glu Ser Trp Ala He Lys Gly Ser 365 370 375 380 Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys Lys Ser Gly 385 390 395 Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg Ser Lys Asp 400 405 410 Thr Glu Lys Arg Leu Lys Thr He Ser Glu Asn Ala Phe Gin Ser Leu 415 420 425 Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys Lys Gly He He Asn 430 435 440 Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr Asp He Leu Arg Gin 445 450 455 460 Lys Ser Val Glu Asn Tyr Pro Thr Thr He Ser Ser Thr Thr Glu Asn 465 470 475 Asn Gin Thr Glu Gin Ser Ser Thr Ser Thr Lys Thr Thr Thr Pro Asn 480 485 490 Leu Thr Phe Glu Asp Ala Met Lys Leu Gly Leu Ala Leu Tyr Leu Asp 495 500 505 Tyr Ala He Pro He Ala Ser He Ser Thr Glu Ala Tyr Val Val Pro 510 515 520 Tyr He Gly Ala Tyr He Leu Gly Pro Ser Asn Lys Leu Ser Ser Asp 525 530 535 540 Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser Leu Glu Lys Leu He 545 550 555 Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser Asn Asn He He Glu 560 565 570 Leu Ala Asn Lys Asn Thr Asn Asn Ala Ala He Gly Ser Ala Phe Leu 575 580 585 Gin Phe Lys He Ala Tyr Ser Gly Ser * 590 595 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrelia afzelii (B) STRAIN: ACAI (vii) IMMEDIATE SOURCE: (B) CLONE: pJB-104 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:303..2162 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION:303..365 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION:366..2159 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: TCAAAAACAA TAACTTACGC TTTATACTAC ATTCTAGCAA CAGGATTACT GGTTTATTTA 60 GTATAAATTA ATCATTTAAA ATAAATAAGA TTAGTTGACA ATACAATTAA TCTTATTTAT 120 AAATTTGAAT AGTATAAAAT CACAAATACC AATATGATAT TGAATTTTTA TCTAATAGTT 180 TTAATATTGT ATACATGTTA TTATGTACAA TAAGTAATAT GTATTATATA TATATTATTA 240 AGACGTTTAA AAAATAACTA AAACTAATAA AAAGTTTATA GTTACAACAG GAAGGTATAA 300 TT ATG AAA AAT CAT ATT TTA TAT AAA TTA ATT ATA TTT TTA ACC ACA 347 Met Lys Asn His He Leu Tyr Lys Leu He He Phe Leu Thr Thr -21 -20 -15 -10 TCT GCA GCA ATA TTT GCA GCA GAC GCA TTA AAG GAA AAA GAT ATA TTT 395 Ser Ala Ala He Phe Ala Ala Asp Ala Leu Lys Glu Lys Asp He Phe -5 1 5 10 AAA ATA AAC CCG TGG ATA CCG ACA TTT GGA TTT GAA AAC ACA AGT GAA 443 Lys He Asn Pro Trp He Pro Thr Phe Gly Phe Glu Asn Thr Ser Glu 15 20 25 TTC AGA TTT GAT ATG GAT GAA CTT GTC CCT GGG TTT GAA AAC AAA AGT 491 Phe Arg Phe Asp Met Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser 30 35 40 AAA ATT ACT ATT AAA CTT AAA CCA TTT GAA ACT AAT CCA GAA TTA GGC 539 Lys He Thr He Lys Leu Lys Pro Phe Glu Thr Asn Pro Glu Leu Gly 45 50 55 AAA GAC GAT CCA TTT TCA GCT TAC ATT AAA GTG GAA GAT CTT GCA TTA 587 Lys Asp Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu 60 65 70 AAA GCA GAA GGC AAA AAA GAC GCT CAA TTC AAA ATC GAT GTA GGA GAT 635 Lys Ala Glu Gly Lys Lys Asp Ala Gin Phe Lys He Asp Val Gly Asp 75 80 85 90 ATA ACA GCC CAA ATT AAT ATA TAC GAT TTT TTT ATT AAA ATA AGT ACT 683 He Thr Ala Gin He Asn He Tyr Asp Phe Phe He Lys He Ser Thr 95 100 105 ATG ACG GAT TTT GAC TTT AAT AAA GAA TCT TTA TTT AGC TTT GCG CCT 731 Met Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro 110 115 120 ATG ACT GGA TTC AAA AGC ACT TAC TAT GGA TTC CCA AGT AAT GAT AGA 779 Met Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser Asn Asp Arg 125 130 135 GCA GTA AGA GGG ACA ATT CTT GCA AGA GGT ACT TCT AAA AAC ATA GGA 827 Ala Val Arg Gly Thr He Leu Ala Arg Gly Thr Ser Lys Asn He Gly 140 145 150 ACA ATT CAA CTG GGA TAC AAA CTC CCA CAA ATC GAC CTT ACA TTT GCA 875 Thr He Gin Leu Gly Tyr Lys Leu Pro Gin He Asp Leu Thr Phe Ala 155 160 165 170 ATA GGA GGA ACA GGC ACA GGT AAT AGA AAT CAA GAG AAT GAC AAA GAC 923 He Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp 175 180 185 ACT CCA TAC AAT AAA ACC TAT CAA GGA ATC CTT TAT GGA ATT CAA GCA 971 Thr Pro Tyr Asn Lys Thr Tyr Gin Gly He Leu Tyr Gly He Gin Ala 190 195 200 ACA TGG AAG CCA ATA AAA AAT ATA CTT GAT CAA AAC GAA GAT ACT CAA 1019 Thr Trp Lys Pro He Lys Asn He Leu Asp Gin Asn Glu Asp Thr Gin 205 210 215 TCT GTA ATT GCA GAA ACA CCT TTT GAA TTA AAC TTT GGC TTA TCA GGA 1067 Ser Val He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly 220 225 230 GCT TAT GGA AAT GAA ACA TTC AAT AAT TCA TCA ATA ACA TAC TCT TTA 1115 Ala Tyr Gly Asn Glu Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu 235 240 245 250 AAA GAT AAA TCC CTA ATT GGT AAC GAT TTA TTA AGC CCA ACT TTA TCA 1163 Lys Asp Lys Ser Leu He Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser 255 260 265 AAT TCT GCA ATT TTG GCA TCT TTT GGA GCT CAA TAT AAG CTT GGA TTA 1211 Asn Ser Ala He Leu Ala Ser Phe Gly Ala Gin Tyr Lys Leu Gly Leu 270 275 280 ACA AAA ATC AAT AAT AAA AAT ACC TAT CTT ATT TTA CAA ATG GGT ACT 1259 Thr Lys He Asn Asn Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr 285 290 295 GAT TTT GGA ATA GAT CCT TTT GCA AGC GAT TTT TCT GTA TTT GGA CAC 1307 Asp Phe Gly He Asp Pro Phe Ala Ser Asp Phe Ser Val Phe Gly His 300 305 310 ATC TCA AAA GCA GCA AAT TTG AAA AAA GGA ATA TCT TTA GAT CCT AGT 1355 He Ser Lys Ala Ala Asn Leu Lys Lys Gly He Ser Leu Asp Pro Ser 315 320 325 330 AAA AAA GCC GAG GAT ATA TTT GAT CCA AAT GGC AAT GCC CTT AAT TTC 1403 Lys Lys Ala Glu Asp He Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe 335 340 345 AAT AAA AAT ACA GAA CTA GGC ATT GCA TTT TCA ACA GGA GCA AGC ATA 1451 Asn Lys Asn Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala Ser He 350 355 360 GGG CTT GCT TGG AAT AAA GAC GAC GGT GAA AAA GAA TCT TGG AAA GTT 1499 Gly Leu Ala Trp Asn Lys Asp Asp Gly Glu Lys Glu Ser Trp Lys Val 365 370 375 AAA GGA TCT GAT TCC TAC AGT ACA AGA CTA TTT GGA GAA CAA GAC AAA 1547 Lys Gly Ser Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys 380 385 390 AAA TCT GGA GTT GCA TTA GGA ATA AGC TAT GGG CAA AAT CTT TAC AGA 1595 Lys Ser Gly Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg 395 400 405 410 TCT AAA GAT ACA GAA AAA AGA TTA AAA ACC ATA TCT GAA AAT GCA TTT 1643 Ser Lys Asp Thr Glu Lys Arg Leu Lys Thr lie Ser Glu Asn Ala Phe 415 420 425 CAA AGC TTA AAT GTT GAA ATT TCA AGC TAT GAA GAC AAT AAA AAG GGG 1691 Gin Ser Leu Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys Lys Gly 430 435 440 CTT ATG AAT GGA CTG GGT TGG ATA ACA TCT ATC GGT CTT TAT GAT ATT 1739 Leu Met Asn Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr Asp He 445 450 455 TTA AGA CAA AAA TCT GTA GAA AAC TAT CCT ACA TCA ACC TTA AGT GCT 1787 Leu Arg Gin Lys Ser Val Glu Asn Tyr Pro Thr Ser Thr Leu Ser Ala 460 465 470 AAT GAG AAC AAT CAA GCT GGA CAA AGT TCA ACA GGC ACA CAA GCC ATA 1835 Asn Glu Asn Asn Gin Ala Gly Gin Ser Ser Thr Gly Thr Gin Ala He 475 480 485 490 ACA CCT AAT CTA ACA TTT GAA GAC GCA ATG AAA CTA GGC ATA GCT TTA 1883 Thr Pro Asn Leu Thr Phe Glu Asp Ala Met Lys Leu Gly He Ala Leu 495 500 505 TAT CTT GAT TAT GCA ATT CCA ATA GAA TCC ATT TCA ACA GAA GCA TAT 1931 Tyr Leu Asp Tyr Ala He Pro He Glu Ser He Ser Thr Glu Ala Tyr 510 515 520 GTA GTA CCA TAT ATT GGA GCA TAC CTT TTA GGA CCT TCT AAT AAA ATA 1979 Val Val Pro Tyr He Gly Ala Tyr Leu Leu Gly Pro Ser Asn Lys He 525 530 535 TCA AGC GAT GCT ACA AAA ATT TAT TTA AAA ACA GGA CTT AGT CTT GAA 2027 Ser Ser Asp Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser Leu Glu 540 545 550 AAA CTA ATA AGA TTT ACA ACA ATT TCT CTT GGA TGG GAT TCA AAT AAT 2075 Lys Leu He Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser Asn Asn 555 560 565 570 ATT ATA GAA CTT GCT AAT AAA AAC GCA AAT AAT GCT GCT ATT GGC AGT 2123 He He Glu Leu Ala Asn Lys Asn Ala Asn Asn Ala Ala He Gly Ser 575 580 585 GCT TTC TTG CAA TTC AAA ATA GCC TAC AGC GGA AGC TAA CAGCAAAAGA 2172 Ala Phe Leu Gin Phe Lys He Ala Tyr Ser Gly Ser * 590 595 AGGGCCAAAA GCCCTTCTTT TTTATCTTTA AAAACAAATT AATCAATTAA TTACTTAATA 2232 TTTCTTTCTT TGCAAATCTT TTCATAAGCA TC 2264 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 619 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Lys Asn His He Leu Tyr Lys Leu He He Phe Leu Thr Thr Ser -21 -20 -15 -10 Ala Ala He Phe Ala Ala Asp Ala Leu Lys Glu Lys Asp He Phe Lys -5 1 5 10 He Asn Pro Trp He Pro Thr Phe Gly Phe Glu Asn Thr Ser Glu Phe 15 20 25 Arg Phe Asp Met Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser Lys 30 35 40 He Thr He Lys Leu Lys Pro Phe Glu Thr Asn Pro Glu Leu Gly Lys 45 50 55 Asp Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu Lys 60 65 70 75 Ala Glu Gly Lys Lys Asp Ala Gin Phe Lys He Asp Val Gly Asp He 80 85 90 Thr Ala Gin He Asn He Tyr Asp Phe Phe He Lys He Ser Thr Met 95 100 105 Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro Met 110 115 120 Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser Asn Asp Arg Ala 125 130 135 Val Arg Gly Thr He Leu Ala Arg Gly Thr Ser Lys Asn He Gly Thr 140 145 150 155 He Gin Leu Gly Tyr Lys Leu Pro Gin He Asp Leu Thr Phe Ala He 160 165 170 Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp Thr 175 180 185 Pro Tyr Asn Lys Thr Tyr Gin Gly He Leu Tyr Gly He Gin Ala Thr 190 195 200 Trp Lys Pro He Lys Asn He Leu Asp Gin Asn Glu Asp Thr Gin Ser 205 210 215 Val He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly Ala 220 225 230 235 Tyr Gly Asn Glu Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu Lys 240 245 250 Asp Lys Ser Leu He Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser Asn 255 260 265 Ser Ala He Leu Ala Ser Phe Gly Ala Gin Tyr Lys Leu Gly Leu Thr 270 275 280 Lys He Asn Asn Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr Asp 285 290 295 Phe Gly He Asp Pro Phe Ala Ser Asp Phe Ser Val Phe Gly His He 300 305 310 315 Ser Lys Ala Ala Asn Leu Lys Lys Gly He Ser Leu Asp Pro Ser Lys 320 325 330 Lys Ala Glu Asp He Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe Asn 335 340 345 Lys Asn Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala Ser He Gly 350 355 360 Leu Ala Trp Asn Lys Asp Asp Gly Glu Lys Glu Ser Trp Lys Val Lys 365 370 375 Gly Ser Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys Lys 380 385 390 395 Ser Gly Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg Ser 400 405 410 Lys Asp Thr Glu Lys Arg Leu Lys Thr He Ser Glu Asn Ala Phe Gin 415 420 425 Ser Leu Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys Lys Gly Leu 430 435 440 Met Asn Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr Asp He Leu 445 450 455 Arg Gin Lys Ser Val Glu Asn Tyr Pro Thr Ser Thr Leu Ser Ala Asn 460 465 470 475 Glu Asn Asn Gin Ala Gly Gin Ser Ser Thr Gly Thr Gin Ala He Thr 480 485 490 Pro Asn Leu Thr Phe Glu Asp Ala Met Lys Leu Gly He Ala Leu Tyr 495 500 505 Leu Asp Tyr Ala He Pro He Glu Ser He Ser Thr Glu Ala Tyr Val 510 515 520 Val Pro Tyr He Gly Ala Tyr Leu Leu Gly Pro Ser Asn Lys He Ser 525 530 535 Ser Asp Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser Leu Glu Lys 540 545 550 555 Leu He Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser Asn Asn He 560 565 570 He Glu Leu Ala Asn Lys Asn Ala Asn Asn Ala Ala He Gly Ser Ala 575 580 585 Phe Leu Gin Phe Lys He Ala Tyr Ser Gly Ser * 590 595 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2547 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrlia garinii (B) STRAIN: Ip90 (vii) IMMEDIATE SOURCE: (B) CLONE: pJB-101 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:380..2245 ( ix) FEATURE : (A) NAME/KEY: sig_peptide (B) LOCATION:380..442 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION:443..2242 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: AAGCTTTTGT CAAAAACAAT ACCTTACGCT TTATACTACA TTCTAGCAAC AGGATTGCTA 60 GTTTATTTAG TATAAATTAA TCATTTAAAA TAAATAAGAT TAATTTACAA TAAAATTAAT 120 CTTATTTATA GATTTGAATA ATATAAAAAT CATAAAATAA TAATATGATC TTGAATTTTT 180 ACCTAATATT TTAATATTAT ATACATGTTA TATATATATT ATTATATGCA TAATAGCATG 240 TATATAATAT ATTTTAGCAT AATAGCATGT ATATAATATA TTTTAGCATA ATAGCATGTA 300 TATAATATAT TTTATTAATG CGTTTAATAA ATAACTAGAA CTAATAAAAA GTTTATAGTT 360 ACAACAGGAA GGTATAATT ATG AAA AAT CAT ATT TTA TAT AAA TTA ATT ATA 412 Met Lys Asn His He Leu Tyr Lys Leu He He -21 -20 -15 TTT TTA ACT ACA TCT GTA GCA ATA TTT GCA GCA GCA GAT AAA TTA AAG 460 Phe Leu Thr Thr Ser Val Ala He Phe Ala Al? Ala Asp Lys Leu Lys -10 -5 1 5 GAA GAA GAT ATA TTT AAA ATA AAT CCA TGG ATA CCT ACA TTT GGA ATT 508 Glu Glu Asp He Phe Lys He Asn Pro Trp He Pro Thr Phe Gly He 10 15 20 GAA AAC ACA AGT GAG TTC AGA CTT GAT ATG GAT GAG CTT GTT CCT GGA 556 Glu Asn Thr Ser Glu Phe Arg Leu Asp Met Asp Glu Leu Val Pro Gly 25 30 35 TTT GAA AAC AAA AGC AAA ATT ACT ATT AAA CTT AAA CCA TTT GAA GTT 604 Phe Glu Asn Lys Ser Lys He Thr He Lys Leu Lys Pro Phe Glu Val 40 45 50 AAT CCC GAA TTA GGC AAA GAC GAC CCA TTC TCA GCT TAC ATT AAG GTA 652 Asn Pro Glu Leu Gly Lys Asp Asp Pro Phe Ser Ala Tyr He Lys Val 55 60 65 70 GAA GAT CTT GCA TTA AAA GCG GAA GGT AAA AAA GGG GAT CCA TTT AAA 700 Glu Asp Leu Ala Leu Lys Ala Glu Gly Lys Lys Gly Asp Pro Phe Lys 75 80 85 ATT GAC GTA GGA GAC ATA ACA GCC CAA ATT AAT ATA TAC GAT TTT TTT 748 He Asp Val Gly Asp He Thr Ala Gin He Asn He Tyr Asp Phe Phe 90 95 100 ATT AAG ATA AGC ACT ATG ACA GAT TTT GAC TTT AAT AAA GAA TCT TTA 796 He Lys He Ser Thr Met Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu 105 110 115 TTT AGT TTT GCG CCC ATG ACC GGA TTC AAA AGC ACT TAC TAC GGA TTT 844 Phe Ser Phe Ala Pro Met Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe 120 125 130 CCA AGC AAA GAC AGA ATA GTA AGA GGA ACA ATT CTT GCA AGA GGT GCT 892 Pro Ser Lys Asp Arg He Val Arg Gly Thr He Leu Ala Arg Gly Ala 135 140 145 150 TCT AAA AAC ATA GGA ACA ATT CAA ATG GGA TAC AAG CTC CCA CAA ATA 940 Ser Lys Asn He Gly Thr He Gin Met Gly Tyr Lys Leu Pro Gin He 155 160 165 GAC CTT ACA TTT GCA ATA GGG GGA ACA GGC ACA GGT AAC AGA AAT CAA 988 Asp Leu Thr Phe Ala He Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin 170 175 180 GAG AAT GAC AAA GAC ACT CCA TAC AAT AAA ACC TAT AAA GGA ATA CTT 1036 Glu Asn Asp Lys Asp Thr Pro Tyr Asn Lys Thr Tyr Lys Gly He Leu 185 190 195 TAT GGG GTT CAA GCA ACA TGG AAG CCA ATA AAA AAT CTA CTT GAT AAA 1084 Tyr Gly Val Gin Ala Thr Trp Lys Pro He Lys Asn Leu Leu Asp Lys 200 205 210 AAC GAA GAT AAT CGA TCT GTA ATT GCA GAA ACA CCT TTT GAA TTA AAT 1132 Asn Glu Asp Asn Arg Ser Val He Ala Glu Thr Pro Phe Glu Leu Asn 215 220 225 230 TTT GGC TTA TCA GGA GCT TAT GGA AAT AAA ACA TTC AAT AAT TCA TCA 1180 Phe Gly Leu Ser Gly Ala Tyr Gly Asn Lys Thr Phe Asn Asn Ser Ser 235 240 245 ATA ACA TAC TCT TTA AAA GAT AAA TCT GTA GTT GGT AAC GAT TTA TTG 1228 He Thr Tyr Ser Leu Lys Asp Lys Ser Val Val Gly Asn Asp Leu Leu 250 255 260 AGT CCA ACT TTA TCA AAT TCT GCA ATT TTA GCA TCT TTT GGA GCT CAA 1276 Ser Pro Thr Leu Ser Asn Ser Ala He Leu Ala Ser Phe Gly Ala Gin 265 270 275 TAT AAG CTT GGA TTA ACA AAA ATC AAC AAT AAA AAT ACC TAT CTT ATT 1324 Tyr Lys Leu Gly Leu Thr Lys He Asn Asn Lys Asn Thr Tyr Leu He 280 285 290 TTA CAA ATG GGT ACC GAT TTT GGA ATA GAT CCT TTT GCA AGC GAT TTT 1372 Leu Gin Met Gly Thr Asp Phe Gly He Asp Pro Phe Ala Ser Asp Phe 295 300 305 310 TCT GTA TTT GGA CAC ATC TCA AAA GCA GCA AAT TCT AAA AAA GGA ATA 1420 Ser Val Phe Gly His He Ser Lys Ala Ala Asn Ser Lys Lys Gly He 315 320 325 TCC GTA GAT CCT ATT AAA AAA GCC GAA GAT ATA TTT GAT CCA AAT GGC 1468 Ser Val Asp Pro He Lys Lys Ala Glu Asp He Phe Asp Pro Asn Gly 330 335 340 AAT GCT CTT AAT TTC AGT AAA AAT ACA GAG CTG GGC ATT GCA TTT TCA 1516 Asn Ala Leu Asn Phe Ser Lys Asn Thr Glu Leu Gly He Ala Phe Ser 345 350 355 ACA GGA GCA AGC ATA GGG CTT CTC TGG AAT AAA GAC GAC GGT GAA AAA 1564 Thr Gly Ala Ser He Gly Leu Leu Trp Asn Lys Asp Asp Gly Glu Lys 360 365 370 GAA TCT TGG AAG GTT AAG GGA GCT GAT TCC TAC AGT ACA AGA CTA TTT 1612 Glu Ser Trp Lys Val Lys Gly Ala Asp Ser Tyr Ser Thr Arg Leu Phe 375 380 385 390 GGA GAA CAA GAC AAA AAA TCT GGA GTT GCA TTA GGA ATA AGT TAT GGA 1660 Gly Glu Gin Asp Lys Lys Ser Gly Val Ala Leu Gly He Ser Tyr Gly 395 400 405 CAA AAT CTT TAT AGA TCC AAA GAT ACA GAA AAA AGA TTA AAA ACC ATA 1708 Gin Asn Leu Tyr Arg Ser Lys Asp Thr Glu Lys Arg Leu Lys Thr He 410 415 420 TCC GAA AAT GCA TTT CAA AGC TTA AAT GTT GAA ATC TCA AGC TAT GAA 1756 Ser Glu Asn Ala Phe Gin Ser Leu Asn Val Glu He Ser Ser Tyr Glu 425 430 435 GAC AAC AAA AAA GGA CTT ATG AAC GGA CTA GGA TGG ATA ACA TCT ATC 1804 Asp Asn Lys Lys Gly Leu Met Asn Gly Leu Gly Trp He Thr Ser He 440 445 450 GGT CTT TAT GAT ATT TTA AGA CAA AAA TCT GTP GAA AAC TAT CCC ACA 1852 Gly Leu Tyr Asp He Leu Arg Gin Lys Ser Val Glu Asn Tyr Pro Thr 455 460 465 470 ACA ACA AGC TCA GCT GCT GAT GCA AAC AAT CAA GCC GGA CAA AGT TCA 1900 Thr Thr Ser Ser Ala Ala Asp Ala Asn Asn Gin Ala Gly Gin Ser Ser 475 480 485 GGA AGC ACA CAA GCT ACA ACC CCT AAT CTA ACA TTT GAA GAC GCA ATG 1948 Gly Ser Thr Gin Ala Thr Thr Pro Asn Leu Thr Phe Glu Asp Ala Met 490 495 500 AAA CTC GGT ATA GCT TTA TAT CTT GAT TAT GCA ATT CCA ATA GAA TCC 1996 Lys Leu Gly He Ala Leu Tyr Leu Asp Tyr Ala He Pro He Glu Ser 505 510 515 ATT TCA ACA GAA GCA TAT GTA GTA CCT TAT ATT GGG GCA TAC CTT TTA 2044 He Ser Thr Glu Ala Tyr Val Val Pro Tyr He Gly Ala Tyr Leu Leu 520 525 530 GGG CAT TTT AAT AAA ATC TCA AGC GAT GCT ACA AAA ATT TAT TTA AAG 2092 Gly His Phe Asn Lys He Ser Ser Asp Ala Thr Lys He Tyr Leu Lys 535 540 545 550 ACA GGA CTT AGT CTT GAA AAA CTA ATA AGA TTT ACA ACA ATT TCT CTT 2140 Thr Gly Leu Ser Leu Glu Lys Leu He Arg Phe Thr Thr He Ser Leu 555 560 565 GGC TGG GAT TCA AAT AAC ATT ATA GAA CTT GCT AAT AAA AAC ACA AAT 2188 Gly Trp Asp Ser Asn Asn He He Glu Leu Ala Asn Lys Asn Thr Asn 570 575 580 AAT GCT GCC ATT GGT AGT GCT TTC TTG CAA TTC AAA ATA GCC TAC AGT 2236 Asn Ala Ala He Gly Ser Ala Phe Leu Gin Phe Lys He Ala Tyr Ser 585 590 595 GGA AGC TAA AAGCAAAAGA AGGGCTTTAG GCCCTTCTTT TTTTATCTTT 2285 Gly Ser * 600 AAAAACAAAT TAATATTAAT TACTTTATAT TTCTTTCTTT GCAAATCTTT TCATAAGCAT 2345 CTTGAATTTT AATAAATTTA TCATTTGCAT CTTTTTGCCT TACAGGATCA TTTGCAAACC 2405 TGTCAGGATG ATATTTTATA ACAAGACTTT TATAAGCCTT TTTAATCTCA TCATCACTAG 2465 CACTATAGAC TAACCCCAAA ACACTATAGG GATTTACAAT TTTAATATTA ATATCTTTAT 2525 AAGCTTCATA ACCATCAGAT TC 2547 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 621 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Lys Asn His He Leu Tyr Lys Leu He He Phe Leu Thr Thr Ser -21 -20 -15 -10 Val Ala He Phe Ala Ala Ala Asp Lys Leu Lys Glu Glu Asp He Phe -5 1 5 10 Lys He Asn Pro Trp He Pro Thr Phe Gly He Glu Asn Thr Ser Glu 15 20 25 Phe Arg Leu Asp Met Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser 30 35 40 Lys He Thr He Lys Leu Lys Pro Phe Glu Val Asn Pro Glu Leu Gly 45 50 55 Lys Asp Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu 60 65 70 75 Lys Ala Glu Gly Lys Lys Gly Asp Pro Phe Lys He Asp Val Gly Asp 80 85 90 He Thr Ala Gin He Asn He Tyr Asp Phe Phe He Lys He Ser Thr 95 100 105 Met Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro 110 115 120 Met Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser Lys Asp Arg 125 130 135 He Val Arg Gly Thr He Leu Ala Arg Gly Ala Ser Lys Asn He Gly 140 145 150 155 Thr He Gin Met Gly Tyr Lys Leu Pro Gin He Asp Leu Thr Phe Ala 160 165 170 He Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp 175 180 185 Thr Pro Tyr Asn Lys Thr Tyr Lys Gly He Leu Tyr Gly Val Gin Ala 190 195 200 Thr Trp Lys Pro He Lys Asn Leu Leu Asp Lys Asn Glu Asp Asn Arg 205 210 215 Ser Val He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly 220 225 230 235 Ala Tyr Gly Asn Lys Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu 240 245 250 Lys Asp Lys Ser Val Val Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser 255 260 ._ 265 Asn Ser Ala He Leu Ala Ser Phe Gly Ala Gin Tyr Lys Leu Gly Leu 270 275 280 Thr Lys He Asn Asn Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr 285 290 295 Asp Phe Gly He Asp Pro Phe Ala Ser Asp Phe Ser Val Phe Gly His 300 305 310 315 He Ser Lys Ala Ala Asn Ser Lys Lys Gly He Ser Val Asp Pro He 320 325 330 Lys Lys Ala Glu Asp He Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe 335 340 345 Ser Lys Asn Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala Ser He 350 355 360 Gly Leu Leu Trp Asn Lys Asp Asp Gly Glu Lys Glu Ser Trp Lys Val 365 370 375 Lys Gly Ala Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys 380 385 390 395 Lys Ser Gly Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg 400 405 410 Ser Lys Asp Thr Glu Lys Arg Leu Lys Thr He Ser Glu Asn Ala Phe 415 420 425 Gin Ser Leu Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys Lys Gly 430 435 440 Leu Met Asn Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr Asp He 445 450 455 Leu Arg Gin Lys Ser Val Glu Asn Tyr Pro Thr Thr Thr Ser Ser Ala 460 465 470 475 Ala Asp Ala Asn Asn Gin Ala Gly Gin Ser Ser Gly Ser Thr Gin Ala 480 485 490 Thr Thr Pro Asn Leu Thr Phe Glu Asp Ala Met Lys Leu Gly He Ala 495 500 505 Leu Tyr Leu Asp Tyr Ala He Pro He Glu Ser He Ser Thr Glu Ala 510 515 520 Tyr Val Val Pro Tyr He Gly Ala Tyr Leu Leu Gly His Phe Asn Lys 525 530 535 He Ser Ser Asp Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser Leu 540 545 550 555 Glu Lys Leu He Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser Asn 560 565 570 Asn He He Glu Leu Ala Asn Lys Asn Thr Asn Asn Ala Ala He Gly 575 580 585 Ser Ala Phe Leu Gin Phe Lys He Ala Tyr Ser Gly Ser * 590 595 600 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 64 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrlia burgdorferi (B) STRAIN: B31 (vii) IMMEDIATE SOURCE: (B) CLONE: p B-105 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:14..61 ( ix) FEATURE : (A) NAME/KEY: sig_peptide (B) LOCATION:14..61 (D) OTHER INFORMATION:/partial /label= partial (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GGAGGGTATA ATT ATG AAA AGC CAT ATT TTA TAT AAA TTA ATC ATA TTT 49 Met Lys Ser His He Leu Tyr Lys Leu He He Phe 605 610 TTA ACC ACA TCT GCA 64 Leu Thr Thr Ser 615 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Lys Ser His He Leu Tyr Lys Leu He UP Phe Leu Thr Thr Ser 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GCAATATTTG CTGCAGCAGA T 21 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GGCCTAAAGG AATTCTTTTG C 21 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2031 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Borrelia burgdorferi (B) STRAIN: B31 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:14..1870 (ix) FEATURE: (A) NAME/KEY: sig_peptide (B) LOCATION:14..76 (ix) FEATURE: (A) NAME/KEY: mat_peptide (B) LOCATION:77..1867 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GGAGGGTATA ATT ATG AAA AGC CAT ATT TTA TAT AAA TTA ATC ATA TTT 49 Met Lys Ser His He Leu Tyr Lys Leu He He Phe -21 -20 -15 -10 TTA ACC ACA TCT GCA GCA ATA TTT GCA GCA GAC GCA TTA AAG GAA AAA 97 Leu Thr Thr Ser Ala Ala He Phe Ala Ala Asp Ala Leu Lys Glu Lys -5 1 5 GAT ATA TTT AAA ATA AAC CCA TGG ATG CCA ACA TTT GGA TTT GAA AAC 145 Asp He Phe Lys He Asn Pro Trp Met Pro Thr Phe Gly Phe Glu Asn 10 15 20 ACA AGT GAA TTC AGA TTA GAT ATG GAC GAG CTT GTT CCT GGG TTT GAA 193 Thr Ser Glu Phe Arg Leu Asp Met Asp Glu Leu Val Pro Gly Phe Glu 25 30 35 AAC AAA AGC AAA ATT ACC ATT AAG CTT AAA CCA TTT GAA GCT AAT CCC 241 Asn Lys Ser Lys He Thr He Lys Leu Lys Pro Phe Glu Ala Asn Pro 40 45 50 55 GAA TTA GGC AAA GAC GAT CCA TTC TCA GCT TAC ATT AAG GTA GAA GAT 289 Glu Leu Gly Lys Asp Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp 60 65 70 CTT GCA CTA AAA GCG GAA GGC AAA AAA GGC GAT CAA TTT AAA ATT GAC 337 Leu Ala Leu Lys Ala Glu Gly Lys Lys Gly Asp Gin Phe Lys He Asp 75 80 85 GTG GGA GAT ATT ACA GCC CAA ATC AAT ATG TAC GAT TTT TTT ATT AAA 385 Val Gly Asp lie Thr Ala Gin He Asn Met Tyr Asp Phe Phe He Lys 90 95 100 ATA AGT ACT ATG ACA GAT TTT GAC TTT AAT AAA GAG TCT TTA TTT AGT 433 He Ser Thr Met Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser 105 110 115 TTT GCA CCT ATG ACT GGA TTT AAA AGC ACT TAC TAT GGA TTC CCA AGC 481 Phe Ala Pro Met Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser 120 125 130 135 AAT GAT AGG GCA GTA AGA GGG ACA ATT CTT GCA AGA GGT ACT TCT AAA 529 Asn Asp Arg Ala Val Arg Gly Thr He Leu Ala Arg Gly Thr Ser Lys 140 145 150 AAC ATA GGA ACA ATT CAG CTG GGA TAC AAA CTC CCA AAA CTC GAC CTT 577 Asn He Gly Thr He Gin Leu Gly Tyr Lys Leu Pro Lys Leu Asp Leu 155 160 165 ACA TTT GCA ATA GGG GGA ACA GGC ACG GGT AAC AGA AAT CAA GAG AAT 625 Thr Phe Ala He Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn 170 175 180 GAC AAA GAC ACT CCA TAC AAT AAA ACA TAT CA1 GGA ATC CTT TAT GGA 673 Asp Lys Asp Thr Pro Tyr Asn Lys Thr Tyr Gin Gly He Leu Tyr Gly 185 190 195 ATT CAA GCA ACA TGG AAA CCA ATA AAA AAT CTA CTT GAT CAA AAC GAA 721 He Gin Ala Thr Trp Lys Pro He Lys Asn Leu Leu Asp Gin Asn Glu 200 205 210 215 GAT ACT AAA TCT GTA ATT GCA GAA ACA CCT TTT GAA TTA AAT TTT GGC 769 Asp Thr Lys Ser Val He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly 220 225 230 TTG TCA GGA GCC TAT GGA AAC GAG ACA TTC AAT AAT TCA TCA ATA ACA 817 Leu Ser Gly Ala Tyr Gly Asn Glu Thr Phe Asn Asn Ser Ser He Thr 235 240 245 TAC TCT TTA AAA GAT AAA TCC GTA GTT GGC AAC GAT, TTA TTG AGC CCA 865 Tyr Ser Leu Lys Asp Lys Ser Val Val Gly Asn Asp Leu Leu Ser Pro 250 255 260 ACT TTA TCA AAT TCT GCA ATT TTA GCA TCT TTT GGA GCT AAA TAT AAG 913 Thr Leu Ser Asn Ser Ala He Leu Ala Ser Phe Gly Ala Lys Tyr Lys 265 270 275 CTT GGA TTA ACA AAA ATA AAC GAT AAA AAT ACC TAT CTT ATT TTG CAA 961 Leu Gly Leu Thr Lys He Asn Asp Lys Asn Thr Tyr Leu He Leu Gin 280 285 290 295 ATG GGA ACT GAT TTT GGA ATA GAT CCT TTT GCA AGC GAT TTT TCT ATA 1009 Met Gly Thr Asp Phe Gly He Asp Pro Phe Ala Ser Asp Phe Ser He 300 305 310 TTT GGA CAC ATC TCA AAA GCA GCG AAT TTC AAA AAA GAA ACA CCC TCA 1057 Phe Gly His lie Ser Lys Ala Ala Asn Phe Lys Lys Glu Thr Pro Ser 315 320 325 GAT CCT AAC AAA AAA GCT GAA ATA TTT GAT CCA AAT GGC AAT GCT CTT 1105 Asp Pro Asn Lys Lys Ala Glu He Phe Asp Pro Asn Gly Asn Ala Leu 330 335 340 AAT TTC AGC AAA AAC ACA GAA TTG GGC ATT GCA TTT TCA ACA GGA GCA 1153 Asn Phe Ser Lys Asn Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala 345 350 355 AGT ATA GGT TTT GCT TGG AAT AAA GAT ACC GGT GAA AAA GAA TCC TGG 1201 Ser He Gly Phe Ala Trp Asn Lys Asp Thr Gly Glu Lys Glu Ser Trp 360 365 370 375 GCG ATT AAA GGA TCT GAT TCC TAC AGT ACA AGA CTC TTT GGA GAA CAA 1249 Ala He Lys Gly Ser Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin 380 385 390 GAC AAA AAA TCT GGA GTT GCA TTG GGA ATA AGC TAT GGA CAA AAC CTT 1297 Asp Lys Lys Ser Gly Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu 395 400 405 TAC AGA TCT AAA GAT ACA GAA AAA AGA TTA AAA ACC ATA TCT GAA AAT 1345 Tyr Arg Ser Lys Asp Thr Glu Lys Arg Leu Lys Thr He Ser Glu Asn 410 415 420 GCA TTT CAA AGC TTA AAT GTT GAA ATT TCA AGC TAT GAA GAC AAC AAA 1393 Ala Phe Gin Ser Leu Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys 425 430 435 AAA GGG ATT ATA AAT GGA TTA GGA TGG ATA ACA TCT ATC GGT CTT TAC 1441 Lys Gly He He Asn Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr 440 445 450 455 GAT ATT TTA AGA CAA AAA TCT GTA GAA AAC TAT CCT ACA ACA ATT TCA 1489 Asp He Leu Arg Gin Lys Ser Val Glu Asn Tyr Pro Thr Thr He Ser 460 465 470 AGC ACC ACT GAA AAC AAT CAA ACT GAA CAA AGT TCA ACA AGC ACA AAG 1537 Ser Thr Thr Glu Asn Asn Gin Thr Glu Gin Ser Ser Thr Ser Thr Lys 475 480 485 ACC ACA ACC CCT AAT CTG ACA TTT GAA GAT GCA ATG AAA CTC GGC TTG 1585 Thr Thr Thr Pro Asn Leu Thr Phe Glu Asp Ala Met Lys Leu Gly Leu 490 495 500 GCC TTA TAT CTT GAT TAT GCA ATT CCA ATA GCA TCC ATT TCA ACA GAA 1633 Ala Leu Tyr Leu Asp Tyr Ala He Pro He Ala Ser He Ser Thr Glu 505 510 515 GCA TAT GTA GTA CCT TAC ATT GGA GCA TAC ATT TTA GGA CCT TCT AAT 1681 Ala Tyr Val Val Pro Tyr He Gly Ala Tyr He Leu Gly Pro Ser Asn 520 525 530 535 AAA CTC TCA AGC GAT GCT ACA AAA ATT TAT TTA AAA ACA GGA CTT AGC 1729 Lys Leu Ser Ser Asp Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser 540 545 550 CTT GAA AAA CTA ATA AGA TTT ACA ACA ATT TCT CTT GGA TGG GAT TCA 1777 Leu Glu Lys Leu He Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser 555 560 565 AAT AAC ATT ATA GAA CTT GCT AAT AAA AAC ACA AAT AAT GCT GCT ATT 1825 Asn Asn He He Glu Leu Ala Asn Lys Asn Thr Asn Asn Ala Ala He 570 575 580 GGA AGT GCT TTC TTG CAA TTC AAA ATA GCC TAC AGC GGA AGC TAA 1870 Gly Ser Ala Phe Leu Gin Phe Lys He Ala Tyr Ser Gly Ser * 585 590 595 CAGCAAAAGA AGGGCTTTGG CCCTTCTTTT TTATCTTTAA AAACAATTGG GATTACCTTA 1930 TATTTCTTTC CTTGCAAATT TTTTCATAAG CATCTTGAAT TTTTATAAAT TTATCATTTG 1990 C-ATCTTTTTG TCTTACAGGA TCATTTGCAA ACTTATCAGG A 2031 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 618 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Lys Ser His He Leu Tyr Lys Leu He He Phe Leu Thr Thr Ser -21 -20 -15 -10 Ala Ala He Phe Ala Ala Asp Ala Leu Lys Glu Lys Asp He Phe Lys -5 1 5 10 He Asn Pro Trp Met Pro Thr Phe Gly Phe Glu Asn Thr Ser Glu Phe 15 20 25 Arg Leu Asp Met Asp Glu Leu Val Pro Gly Phe Glu Asn Lys Ser Lys 30 35 40 He Thr He Lys Leu Lys Pro Phe Glu Ala Asn Pro Glu Leu Gly Lys 45 50 55 Asp Asp Pro Phe Ser Ala Tyr He Lys Val Glu Asp Leu Ala Leu Lys 60 65 70 75 Ala Glu Gly Lys Lys Gly Asp Gin Phe Lys He Asp Val Gly Asp He 80 85 90 Thr Ala Gin He Asn Met Tyr Asp Phe Phe He Lys He Ser Thr Met 95 100 105 Thr Asp Phe Asp Phe Asn Lys Glu Ser Leu Phe Ser Phe Ala Pro Met 110 115 120 Thr Gly Phe Lys Ser Thr Tyr Tyr Gly Phe Pro Ser Asn Asp Arg Ala 125 130 135 Val Arg Gly Thr He Leu Ala Arg Gly Thr Ser Lys Asn He Gly Thr 140 145 150 155 He Gin Leu Gly Tyr Lys Leu Pro Lys Leu Asp Leu Thr Phe Ala He 160 165 170 Gly Gly Thr Gly Thr Gly Asn Arg Asn Gin Glu Asn Asp Lys Asp Thr 175 180 185 Pro Tyr Asn Lys Thr Tyr Gin Gly He Leu Tyr Gly He Gin Ala Thr 190 195 200 Trp Lys Pro He Lys Asn Leu Leu Asp Gin Asn Glu Asp Thr Lys Ser 205 210 215 Val He Ala Glu Thr Pro Phe Glu Leu Asn Phe Gly Leu Ser Gly Ala 220 225 230 235 Tyr Gly Asn Glu Thr Phe Asn Asn Ser Ser He Thr Tyr Ser Leu Lys 240 245 250 Asp Lys Ser Val Val Gly Asn Asp Leu Leu Ser Pro Thr Leu Ser Asn 255 260 265 Ser Ala He Leu Ala Ser Phe Gly Ala Lys Tyr Lys Leu Gly Leu Thr 270 275 280 Lys He Asn Asp Lys Asn Thr Tyr Leu He Leu Gin Met Gly Thr Asp 285 290 295 Phe Gly He Asp Pro Phe Ala Ser Asp Phe Ser He Phe Gly His He 300 305 310 315 Ser Lys Ala Ala Asn Phe Lys Lys Glu Thr Pro Ser Asp Pro Asn Lys 320 325 330 Lys Ala Glu He Phe Asp Pro Asn Gly Asn Ala Leu Asn Phe Ser Lys 335 340 345 Asn Thr Glu Leu Gly He Ala Phe Ser Thr Gly Ala Ser He Gly Phe 350 355 360 Ala Trp Asn Lys Asp Thr Gly Glu Lys Glu Ser Trp Ala He Lys Gly 365 370 375 Ser Asp Ser Tyr Ser Thr Arg Leu Phe Gly Glu Gin Asp Lys Lys Ser 380 385 390 395 Gly Val Ala Leu Gly He Ser Tyr Gly Gin Asn Leu Tyr Arg Ser Lys 400 405 410 Asp Thr Glu Lys Arg Leu Lys Thr He Ser Glu Asn Ala Phe Gin Ser 415 420 425 Leu Asn Val Glu He Ser Ser Tyr Glu Asp Asn Lys Lys Gly He He 430 435 440 Asn Gly Leu Gly Trp He Thr Ser He Gly Leu Tyr Asp He Leu Arg 445 450 455 Gin Lys Ser Val Glu Asn Tyr Pro Thr Thr He Ser Ser Thr Thr Glu 460 465 470 475 Asn Asn Gin Thr Glu Gin Ser Ser Thr Ser Thr Lys Thr Thr Thr Pro 480 485 490 Asn Leu Thr Phe Glu Asp Ala Met Lys Leu Gly Leu Ala Leu Tyr Leu 495 500 505 Asp Tyr Ala He Pro He Ala Ser He Ser Thr Glu Ala Tyr Val Val 510 515 520 Pro Tyr He Gly Ala Tyr He Leu Gly Pro Ser Asn Lys Leu Ser Ser 525 530 535 Asp Ala Thr Lys He Tyr Leu Lys Thr Gly Leu Ser Leu Glu Lys Leu 540 545 55C 555 He Arg Phe Thr Thr He Ser Leu Gly Trp Asp Ser Asn Asn He He 560 565 570 Glu Leu Ala Asn Lys Asn Thr Asn Asn Ala Ala He Gly Ser Ala Phe 575 580 585 Leu Gin Phe Lys He Ala Tyr Ser Gly Ser * 590 595 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) A. The indications made below relate to the microorganism referred to in the description on page £_3 » line 25 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | yj Name of depositary institution Deutsche Sammlung von ikroorganismen und Zellkulturen GmbH (DSM) Address of depositary institution (including postal code and country) Maschroder Weg lb D-38124 Braunschweig Federal Republic of Germany Date of deposit Accession Number 16 June 1994 DSM 9253 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Q As regards the respective Patent Offices of the respective designated states, the applicant requests that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if Hie indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications eg., "Accession Number of Deposit") For International Bureau use only I I This sheet was received by the International Bureau on: Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) For International Bureau use only I [ This sheet was received by the Internationa] Bureau on: Authorized officer INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) The indications made below relate to the microorganism referred to in the description on page 43 , « li-ne- 25 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet | | Name of depositary institution Deutsche Sammlung von Mikroorganis en und Zellkulturen GmbH (DSM) Address of depositary institution (including postal code and country) Maschroder Weg lb D- 38124 Braunschweig Federal Republic of Germany Date of deposit Accession Number 16 June 1994 DSM 9255 C. ADDITION L INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ~~^ As regards the respective Patent Offices of the respective designated states, the applicant requests that a sample of the deposited microorganisms only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if liu indications arc not for all designated Stales) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) Theindicationsiistedbeiowwillbesubmitted to the international Bureau later (specify the general nature of iheindication cg., 'Accession Number of Deposit")

Claims: CLAIMS 1. An isolated nucleic acid fragment which comprises a nucleotide sequence which encodes a polypeptide exhibiting a substantial immunological reac- tivity with a rabbit antiserum raised against a 66 kDa polypeptide derived from Borrelia garinii IP90, said rabbit antiserum exhibiting substantially no immunologi¬ cal reactivity with whole cell preparations from at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica, and/or hybridises readily with either a DNA fragment having the nucleotide sequence SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with a DNA fragment complemen- tary thereto, but exhibits no substantial hybridization with genomic DNA from at least 95% of randomly selected Borrelia hermsii, Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica when the hybridization conditions are highly stringent, 2. The nucleic acid fragment according to claim 1, wherein the 66 kDa polypeptide derived from Borrelia garinii IP90 comprises the amino acid sequence 1-600 of SEQ ID NO: 8. 3. The nucleic acid fragment according to claim 1 or 2, which encodes a polypeptide comprising an amino acid sequence comprised in a polypeptide present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, and/or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii, Borrelia crocidurae, Borrelia anserina, or Borrelia hispanica. 4. The nucleic acid fragment according to any of the prece¬ ding claims, which encodes a polypeptide comprising at least a part of an amino acid sequence of a 66 kDa protein present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, and/or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidu ¬ rae, Borrelia anserina, and Borrelia hispanica. 5. The nucleic acid fragment according to any of the prece¬ ding claims, which encodes a polypeptide comprising at least one epitope present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 6. The nucleic acid fragment according to any of the prece- ding claims, which encodes a polypeptide comprising at least one epitope of a 66 kDa protein present in whole cell pre¬ parations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 7. A nucleic acid fragment according to any of the preceding claims, which comprises a nucleic acid fragment encoding a polypeptide which has substantially the same amino acid sequence as positions 175-190, 285-305, 365-385, or 465-490 in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 14. 8. The nucleic acid fragment according to any of the prece¬ ding claims, which encodes a 66 kDa protein present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of ran¬ domly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 9. The nucleic acid fragment according to claim 8, wherein the encoded protein is present in fraction B from Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. 10. The nucleic acid fragment according to claim 9, wherein the encoded protein natively is a surface exposed protein of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. 11. The nucleic acid fragment according to any of the prece- ding claims, which encodes a polypeptide which has an amino acid sequence exhibiting a sequence homology of at least 50% with SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ NO: 10, or SEQ ID NO: 14 or with subsequences thereof. 12. The nucleic acid fragment according to any of the prece- ding claims, wherein the nucleotide sequence has a sequence homology of at least 70% with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with subsequences thereof. 13. A nucleic acid fragment according to any of the preceding claims, which comprises substantially the nucleotide sequence shown in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or subsequences thereof. 14. A nucleic acid fragment according to any of the preceding claims, which encodes a fusion polypeptide. 15. The nucleic acid fragment according to claim 12 encoding a fusion polypeptide comprising as a fusion partner a polypeptide fragment which enhances the immunogenicity of the fusion polypeptide relative to the immunogenicity of a polypeptide not comprising said second fusion partner or which facilitates the expression of the fusion polypeptide in a host cell and/or the subsequent purification of the polypeptide. 16. The nucleic acid fragment according to claim 14 or 15, which encodes a fusion polypeptide comprising as a fusion partner a polypeptide fragment which has substantially the same amino acid sequence as posi- tions 175-190, 285-305, 365-385, or 465-490 in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 14, is a lipoprotein selected from the outer membrane lipoprotein from E. coli and OspA from Borrelia burgdor¬ feri sensu lato, - is a viral protein selected from Hepatitis B surface antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1, is a immunoglobulin binding protein selected from protein A, protein G, and the ZZ-peptide, - is a T-cell epitope, is a B-cell epitope, is a bacterial fimbrial protein selected from the pilus components pilin and papA, and/or is the maltose binding protein, gluthatione S- transferase, /3-galactosidase, or poly-histidine. 17. The nucleic acid fragment according to any of the prece¬ ding claims, which is a DNA fragment. 18. A substantially pure polypeptide exhibiting a substantial immunological reactivity with an antiserum from rabbits immunised with a 66 kDa polypeptide derived from Borrelia garinii IP90, said rabbit antiserum exhibiting substantially no immunological reactivity with whole cell preparations from at least 95% of randomly selected B. hermsii , B. crocidurae, B. anserina, or B. hispanica. 19. The polypeptide according to claim 18, wherein the 66 kDa polypeptide derived from Borrelia garinii IP90 comprises the amino acid sequence 1-600 of SEQ ID NO: 8. 20. The polypeptide according to claim 18 or 19, which com¬ prises an amino acid sequence comprised in a polypeptide present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii, Borrelia crocidu¬ rae, Borrelia anserina, or Borrelia hispanica. 21. The polypeptide.according to any of claims 18-20, which comprises at least a part of the amino acid sequence of a 66 kDa protein present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 22. A polypeptide according to any of claims 18-21 comprising at least one epitope present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell pre¬ parations of at least 95% of randomly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 23. A polypeptide according to any of claims 18-22, which comprises at least one epitope of a 66 kDa protein present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI but substantially absent from whole cell preparations of at least 95% of ran¬ domly selected Borrelia hermsii , Borrelia crocidurae, Borrelia anserina, and Borrelia hispanica. 24. The polypeptide according to claim any of claims 18-23, which comprises at least one of the amino acid sequences 175- 190, 285-305, 365-385, or 465-490 in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 14. 25. The polypeptide according to any of claims 18-24, which has an amino acid sequence substantially identical to a 66 kDa protein present in whole cell preparations of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. 26. The polypeptide according to claim 25, wherein the 66 kDa protein is present in fraction B from Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. 27. The polypeptide according to claim 25 or 26, wherein the 66 kDa protein is a surface exposed protein of Borrelia burgdorferi B31, Borrelia garinii IP90, or Borrelia afzelii ACAI. 28. The polypeptide according to any of claims 18-27, which has an amino acid sequence exhibiting a sequence homology of at least 50% with SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 14 or with subsequences thereof. 29. A polypeptide according to any of claims 18-28, which is encoded by a nucleotide sequence exhibiting a sequence homology of at least 70% with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13 or with subsequences thereof. 30. The polypeptide according to claim 29 which comprises the amino acid sequence SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 14. 31. The polypeptide according to claim 30, which is encoded by a DNA fragment comprising the nucleotide sequence SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 13. 32. A fusion polypeptide comprising as a first fusion partner the polypeptide according to any of claims 18-31. 33. The fusion polypeptide according to claim 32, which comprises as a second fusion partner a polypeptide fragment which enhances the immunogenicity of the fusion polypeptide relative to the immunogenicity of a polypeptide not compri¬ sing said second fusion partner or which facilitates the expression of the fusion polypeptide in a host cell and/or the subsequent purification of the polypeptide. 34. The fusion polypeptide according to claim 32 or 33, wherein a second fusion partner is a polypeptide which has substantially the same amino acid sequence as positions 175-190, 285-305, 365-385, or 465-490 in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 14, - which is a lipoprotein selected from the outer membrane lipoprotein from E. coli and OspA from Borrelia burgdor¬ feri sensu lato, which is a viral protein selected from Hepatitis B sur¬ face antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1, which is a immunoglobulin binding protein selected from protein A, protein G, and the synthetic ZZ-peptide, which is a T-cell epitope, which is a B-cell epitope, - which is a bacterial fimbrial protein selected from the pilus components pilin and papA, and/or which is the maltose binding protein, gluthatione S- transferase, β-galactosidase, or poly-histidine. 35. A vaccine comprising an amount of the polypeptide accor¬ ding to any of claims 18-34 or of the polypeptide encoded by the nucleic acid fragment according to any of claims 1-17, the amount of the polypeptde being effective to confer sub- stantially increased resistance to infections with Borrelia burgdorferi sensu lato in an animal, including a human being, in combination with a pharmaceutically acceptable carrier or vehicle and the vaccine optionally further comprising an adjuvant. 36. A live vaccine comprising a non-pathogenic microorganism carrying and being capable of expressing the nucleic acid fragment according to any of claims 1-17, the live vaccine being effective in conferring increased resistance to infec¬ tion with Borrelia burgdorferi sensu lato in an animal, including a human being. 37. A vaccine according to claim 35 which is a combination vaccine, further comprising at least one further Borrelia antigen. 38. A combination vaccine according to claim 37, wherein the at least one further Borrelia antigen is selected from the group consisting of OspA, OspB, OspC, OspD, and PC. 39. A combination vaccine comprising at least two different polypeptides according to any of claims 18-34 or at least two polypeptides encoded by the nucleic acid fragment according to any of claims 1-17, the vaccine comprising an amount of the polypeptides effective to confer substantially increased resistance to infections with JBorrelia burgdorferi sensu lato in an animal, including a human being, in combination with a pharmaceutically acceptable carrier or vehicle, the vaccine optionally further comprising an adjuvant. „,„„„ WO 95/35379 40. A vaccine comprising the nucleic acid fragment according to any of claims 1-17, the vaccine effecting in vivo expres- sion of antigens by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigens being effective to confer substantially increased resistance to infections with Borrelia burgdorferi sensu lato in an animal, including a human being. 41. An at least partially purified antibody reacting substan¬ tially specifically with the protein according to any of claims 18-34 or with the protein encoded by the nucleic acid fragment according to any of claims 1-17, the antibody being polyclonal or monoclonal. 42. The antibody according to claim 41, which is a monoclonal antibody. 43. A diagnostic composition adapted for the determination of Borrelia burgdorferi sensu lato in an animal, including a human being, or in a sample, the composition comprising the polypeptide according to claim any of claims 18-34 or the polypeptide encoded by the nucleic acid fragment according to any of claims 1-17, the amount of the polypeptide being effective to detectably react with antibodies present in the animal or in the sample, the antibodies being directed against Borrelia burgdorferi sensu lato, the composition optionally comprising a detectable label. 44. A diagnostic composition adapted for the determination of Borrelia burgdorferi sensu lato in an animal, including a human being, the composition comprising an amount of the nucleic acid fragment according to any of claims 1-17 which is effective to detectably bind to a nucleic acid fragment from Borrelia burgdorferi sensu lato present in the animal or in the sample, the composition optionally comprising a detec¬ table label. 45. A diagnostic composition adapted for the determination of Borrelia burgdorferi sensu lato in an animal, including a human being, or in a sample, the composition comprising an amount of the antibody according to claim 41 or 42 which is effective to detectably react with an antigen from Borrelia burgdorferi sensu lato present in the animal or in the sample, the composition optionally comprising a detectable label. 46. A method of immunizing an animal, including a human being against infections with Borrelia burgdorferi sensu lato, the method comprising administering to the animal an immunogenically effective amount of the vaccine according to any of claims 35-40. 47. A method of passively immunizing an animal, including a human being against infections with Borrelia burgdorferi sensu lato, the method comprising administering to the animal an immunogenically effective amount of the antibody according to claim 41 or 42. 48. A method of determining the presence of antibodies directed against Borrelia burgdorferi sensu lato in an ani¬ mal, including a human being, or in a sample, comprising administering the polypeptide according to any of claims 18- 34 or the polypeptide encoded by the nucleic acid fragment according to any of claims 1-17 to the animal, or incubating the sample with the polypeptide according to any of claims 18-34 or the with the polypeptide encoded by the nucleic acid fragment according to any of claims 1-17, and detecting the presence of bound antibody resulting from the administration or incubation. 49. A method of determining the presence of a Borrelia burg¬ dorferi sensu lato antigen in an animal, including a human being, or in a sample, comprising administering the antibody according to any of claims 35-40 to the animal or incubating the sample with the antibody according to any of claims 35- 40, and detecting the presence of bound antigen resulting from the administration or incubation. 50. A method of determining the presence of Borrelia burgdor¬ feri sensu lato nucleic acids in an animal, including a human being, or in a sample, comprising administering the nucleic acid fragment according to any of claims 1-17 to the animal or incubating the sample with the nucleic acid fragment according to any of claims 1-17, and detecting the presence of hybridized nucleic acids resulting from the incubation. 51. A method of preparing a polypeptide according to any of claims 18-34, comprising - inserting the nucleic acid fragment according to any of claims 1-17 in an expression vector, transforming a host organism or a host cell with the vector, culturing the transformed host cell under conditions facilitating the expression of the polypeptide by the host organism or host cell, and harvesting the polypeptide, and optionally subjecting the polypeptide to post-translational modification(s) ; or - by synthesising the polypeptide by solid-phase peptide synthesis or by liquid-phase peptide synthesis. 52. A method according to claim 51, wherein the expression vector is selected from a plasmid, a cosmid, a minichromoso- me, or a phage; the host cell is a microorganism selected from a bacterium, a yeast, or a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, or a mammalian cell; and the post- translational modifications involves lipidation or glycosylation. 53. A replicable expression vector carrying the nucleic acid fragment according to any of claims 1-17, the vector being capable of replicating in a host organism or cell line. 54. The vector according to claim 53, which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini- chromosome or a virus. 55. A vector according to claim 55 which, when introduced in a host cell, is integrated in the host cell genome. 56. A transformed cell carrying and capable of replicating the nucleic acid fragment according to any of claims 1-17. 57. A transformed cell according to claim 56, which is a microorganism selected from a bacterium, a yeast, a proto¬ zoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, or a mammalian cell. 58. A transformed cell according to claim 57 which is a bacterium of the genus Escherichia, Bacillus or Salmonella. 59. A transformed cell according to claim 58, which is an E. coli cell. 60. A stable cell line producing the polypeptide according to any of claims 18-34. 61. A stable cell line according to claim 60, which carries and expresses the nucleic acid fragment according to any of claims 1-17. 62. A diagnostic kit comprising an antibody according to any of claims 35-40 and a means for detecting the reaction between the antibody and antigen bound thereto, - a polypeptide according to any of claims 18-34 and a means for detecting the reaction between the polypeptide and antibody bound thereto, or a nucleic acid fragment according to any of claims 1-17 and a means for detecting the binding between the nucleic acid fragment and nucleic acid bound thereto.

Inventors: BARBOUR ALAN GEORGE, BERGSTROEM SVEN, BARBOUR, ALAN, GEORGE, BERGSTROEM, SVEN
Applicants: BARBOUR ALAN GEORGE, BERGSTROEM SVEN, SYMBICOM AB, BARBOUR, ALAN, GEORGE, BERGSTROEM, SVEN, SYMBICOM AKTIEBOLAG
Application year: 1995
Main classification: C12N15
IPC codes: A61K39, C07K14, C12N15